SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions January USPTO class listing 01/08

20080025913 - Novel anti-dc-sign antibodies: Antibodies to DC-SIGN are disclosed which are capable of modulating the interaction of dendritic cells and T cells. In some embodiments, the antibodies inhibit the interaction of dendritic cells and T cells. In other embodiments, the antibodies are combined with peptides which are internalized in dendritic cells and presented to... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080025915 - Technetium-and rhenium-bis (heteroaryl) complexes, and methods of use thereof: One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of... Agent: Foley & Lardner LLP

20080025916 - Tailored treatment suitable for different forms of mastocytosis: The present invention relates to a method for a tailored treatment of mastocytosis comprising a) assessing whether or not a c-kit mutation at position 816 is detected in a sample of a patient and b) administering a specific 816 mutant c-kit inhibitor in case a mutation is detected in step... Agent: Foley And Lardner LLP Suite 500

20080025925 - Dental bleaching compositions having long-term rheological stability and devices, kits and methods that utilize such compositions: Dental bleaching compositions include a dental bleaching agent, a generally linear high molecular weight (i.e., greater than about 500,000) polyvinyl pyrrolidone (PVP) and/or polyethylene oxide (PEO) tissue adhesion agent included in amount that imparts a high level of adhesiveness, a rheology-modifying agent such as fumed silica or fumed alumina that... Agent: Workman Nydegger

20080025926 - Oral care formulations with hydrogen peroxide and lycopene: A toothpaste formulation is disclosed which comprises hydrogen peroxide; and cetylpyridinium chloride, and wherein the hydrogen peroxide and the cetylpyridinium chloride have been combined in the toothpaste formulation for not more than about seven minutes prior to administration to an individual. A mouth rinse formulation is disclosed which comprises hydrogen... Agent: Buchanan, Ingersoll & Rooney PC

20080025930 - Anti-aging compositions comprising menyanthes trifoliata leaf extracts and methods of use thereof: An anti-aging composition comprising a skin-beneficial amount of actives identified in Menyanthes trifoliata leaf, wherein the actives are inhibitors of one or more of MMP-1, 2 and 9 and/or scavengers of peroxynitrite. Also disclosed are methods of using such a composition, which include treating the skin for signs of chronological... Agent: The Estee Lauder Cos, Inc

20080025929 - Topical formulations for the treatment of skin conditions: The invention features compositions for topical administration of an oxidatively transformed carotenoid or 2-methyl-6-oxo-2,4-heptadienal and methods of treating skin conditions therewith.... Agent: Clark & Elbing LLP

20080025934 - Cosmetic composition combining a copolymer, a non-volatile oil and a glossy oil: A cosmetic composition includes, in a physiologically acceptable medium, at least: one copolymer containing at least alkyl methacrylate, alkyl acrylate and acrylic acid monomers; one non-volatile oil having a hydrocarbon-based chain containing at least 16 carbon atoms and having a molar mass of less than 650 g/mol; and one glossy... Agent: Oliff & Berridge, PLC

20080025941 - Compositions containing quaternary ammonium compounds: This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that said composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which... Agent: Young & Thompson

20080025943 - Modified two-component gelation systems, methods of use and methods of manufacture: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first... Agent: Blakely Sokoloff Taylor & Zafman

20080025944 - Combination therapy for immunostimulation: The present invention relates to a method for immunostimulation in a mammal, which comprises a. administration of at least one mRNA containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b. administration of at least one cytokine, at least... Agent: Connolly Bove Lodge & Hutz LLP

20080025945 - Use of il-6 in liver injury: The invention relates to the use of IL-6 in liver cirrhosis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080025948 - Methods of treatment using interferon-tau: Methods of modulating cytokine levels in a human subject by administering interferon-tau (IFNτ) are described. More specifically, a method of up-regulating the interleukin 10 (IL-10) level in patients afflicted with a condition that responds to treatment by having an increased blood IL-10 level, such as an autoimmune condition, a viral... Agent: Perkins Coie LLP

20080025949 - Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives: This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous... Agent: Rashida A. Karmali

20080025950 - Modified macromolescules and associated methods of synthesis and use: Described herein are compounds such as macromolecules that have been modified in order to facilitate crosslinking by introduction of at least one hydrazide-reactive group and/or aminooxy-reactive group, and methods of making and using thereof for scar-free wound healing, for delivering bioactive agents or living cells, for preventing adhesion after a... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080025951 - Cytokine antagonist molecules: This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression and/or secretion of cytokines.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080025957 - Stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them: The present invention relates to stem cells suitable for transplantation and to methods for their preparation.... Agent: Marshall, Gerstein & Borun LLP

20080025954 - Use of gingival fibroblasts for vascular cell therapy: The invention relates to the use of gingival fibroblasts for obtaining a cellular composition for treating arterial-remodelling pathology, for example an aneurysm, post-cryoplasty stenosis and restenosis, an aortic dissection or atherosclerosis.... Agent: Alston & Bird LLP

20080025953 - Vigor enhancement of animals via administration of stem cells: Disclosed herein are methods for increasing the vigor of nonhuman vertebrates utilizing stem cells. Unlike methods designed to treat disease conditions, the methods exemplified herein teach the utilization of stem cells for increasing vigor in animals not necessarily for the purpose of treating a disease, but can include application to... Agent: Beusse Wolter Sanks Mora & Maire

20080025961 - Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080025966 - Methods and compositions for the treatment of gastrointestinal disorders: The use of chymotrypsin inhibitors for treating various disorders, including IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic... Agent: Fish & Richardson PC

20080025914 - Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug: The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject with cancer or HIV-1-infected subjects, in order to allow the... Agent: Dla Piper US LLP

20080025917 - Methods for modulating formation and progression of cellulite: This invention provides methods and compositions for modulating the formation and/or progression of cellulite and other skin disorders in a subject.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080025918 - Invisible light fluorescent platelets for intraoperative detection of vascular thrombosis: This invention relates to methods, kits, and compositions for intraoperative detection of aggregates of platelets, e.g., associated with vascular thrombosis, using invisible light fluorophore (IRF)-loaded platelets.... Agent: Fish & Richardson PC

20080025919 - Benzoylguanidine salt and hydrates thereof: 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080025921 - Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease: This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present... Agent: Choate, Hall & Stewart LLP

20080025920 - Methods of treating hot flashes with formulations for transdermal or transmucosal application: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about... Agent: Winston & Strawn LLP Patent Department

20080025922 - Bronzer composition: Bronzer compositions are provided. They comprise (a) water, (b) at least one water-soluble dye; and (c) at least one water-dispersible or water-soluble film-forming polymer. Optionally, a self-tanning agent such as 1,3-dihydroxyacetone may be present.... Agent: Philip S. Johnson Johnson & Johnson

20080025923 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025924 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025927 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025928 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025931 - Cosmetic method for limiting age-related hollowing of the face: Disclosed herein is a cosmetic method for remodelling the face and/or limiting age-related hollowing of the face, by applying to the skin of the face and/or the neck, a composition containing, in a physiologically acceptable medium, at least one extract of a non-fruiting non-photosynthetic filamentous bacterium.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080025932 - Skin care compositions containing a sugar amine: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025933 - Elastic cationic polyurethanes: The invention concerns novel cationic polyurethanes with elastic character, that is having immediate recovery ranging between 5% and 95%, consisting essentially (a1) of cationic units derived from at least a tertiary amine having at least two functions reactive to labile hydrogen, said tertiary amine being at least partly neutralised, (a2)... Agent: Nixon & Vanderhye, PC

20080025935 - Inhibition of sweat malodor: The present invention relates to a method for screening compounds having the ability to prevent, treat or reduce malodor development on body surfaces. In particular, the method allows to efficiently screen for compound having the ability of preventing sweat malodor development caused by volatile sulfur compounds (VSCs). The present invention... Agent: Winston & Strawn LLP Patent Department

20080025937 - Method and composition for permanently shaping hair: or the salt thereof, wherein R1 is a straight chain alkyl residue with about 3 to about 6 carbon atoms or a straight chain hydroxyalkyl residue with about 3 to about 6 carbon atoms, R2 and R3 are hydrogen or straight chain alkyl residues with about 1 to about 3... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025936 - Use of natural zein for improving the condition of hair and agent therefor: The object of the present invention is the use of natural zein for improving the condition of hair, preferably for hardening, strengthening, restructuring or increasing the luster, volume or combability of human hair.... Agent: Striker, Striker & Stenby

20080025938 - Method and composition for permanently shaping hair: (ii) about 0.1% by weight to about 20% by weight of at least one further hair keratin reducing agent selected from the group consisting of thioglycolic acid, thiolactic acid, 3-mercaptopropionic acid, 2-hydroxy-3-mercaptopropionic acid, cysteine, cysteamine, alkyl- or acylcysteamine with about 1 to about 4 carbon atoms in the alkyl residue,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025939 - Method and composition for permanently shaping hair: (ii) about 0.1% by weight to about 15% by weight of at least one alkalizing agent selected from the group consisting of lithium hydroxide, earth alkali metal hydroxides; hydroxyalkyl substituted amines with about 1 to about 3 alkyl residues comprising about 1 to about 4 carbon atom in the alkyl... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025940 - Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof: are useful for caring for and/or making up keratin fibers, especially human keratin fibers, to induce and/or stimulate the growth, to stop the loss and/or to increase the density thereof, and/or to improve the appearance and/or to reduce the canities thereof, and/or to stimulate the pigmentation and/or to limit the... Agent: Buchanan, Ingersoll & Rooney PC

20080025942 - High concentration single phase glycol aerosol air sanitizer with dimethyl ether propellant/solvent: Improved single-phase aerosol spray air sanitizers are disclosed. The preferred active ingredient for the air sanitization is a high concentration of triethylene glycol (TEG), made possible in the single-phase aerosol formulation by the use of dimethyl ether (DME) as a propellant. The combination of TEG and DME enables high concentrations... Agent: S.c. Johnson & Son, Inc.

20080025946 - Interleukin 21 and tyrosine kinase inhibitor combination therapy: The present invention provides methods for use of IL-21 in combination with a tyrosine kinase inhibitor (TKI) in treatment of diseases in which inhibition of phosphorylation via TK inhibition and modulation of immune function play a clinically beneficial role. These diseases include, but are not limited to, cancers, such as... Agent: Zymogenetics, Inc. Intellectual Property Department

20080025947 - Methods for enhancing the efficacy of il-2 mediated immune responses: Methods directed to enhancing the effectiveness of IL-2 in stimulating the immune system is disclosed. According to one method, an antagonist directed against the CD25 subunit of the high-affinity IL-2 receptor complex is administered in conjunction with IL-2. The CD25 antagonist may be an anti-CD25 antibody. According to another method,... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20080025952 - Methods for targeted deliver of genetic material to the liver: The present invention provides methods for enhanced delivery of various therapeutic agents, such as gene therapy agents, to the vasculature of a target organ in a mammalian subject. The methods for targeted gene therapy in the mammalian liver as a whole, or in a single hepatic lobe, are disclosed. The... Agent: Genzyme Corporation Legal Department

20080025958 - Cell-based rna interference and related methods and compositions: This invention provides barcoded shRNA libraries and methods of using same.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080025956 - Blood vessel formation from endothelial colony forming cells: Methods and compositions to form fully functional blood vessels in vivo using endothelial colony forming cells (ECFCs) are disclosed. Culturing ECFCs in a support material results in association of ECFCs in vitro and formation of blood vessels in vivo upon implantation. Direct administration of cultured ECFCs form blood vessels in... Agent: Barnes & Thornburg LLP

20080025955 - Method of producing vascular endothelial cells from primate embryonic stem cells: To provide a method for differentiating primate embryonic stem cells into vascular endothelial cells, and a technique using the method. A method for differentiating primate embryonic stem cells into early developmental vascular endothelial cells comprising differentiating primate embryonic stem cells into vascular endothelial cell parker-positive cell population; the early developmental... Agent: Birch Stewart Kolasch & Birch

20080025959 - Permeability of blood-brain barrier: This relates to a discovery of a cell surface protein, namely NgR2, that is implicated in regulation of blood-brain barrier (BBB). In addition, the invention relates methods for identifying agents that modulate BBB permeability. Furthermore, the invention relates to methods of delivering therapeutic agents to the central nervous system by... Agent: Wilson Sonsini Goodrich & Rosati

20080025960 - Detergents with stabilized enzyme systems: The present invention provides methods and compositions for the stabilization of oxidase enzymes during storage. In some preferred embodiments, the oxidase is a component of liquid detergent compositions. In some particularly preferred embodiments, the oxidase is stabilized by the addition of a reversible inhibitor of the oxidase to a liquid... Agent: Kamrin T. Macknight Danisco US Inc.

20080025962 - Remedy for alzheimer's disease: The present invention provides a prophylactic/therapeutic agent for Alzheimer's disease comprising a substance that inhibits the action of β-amyloid 1-40 to suppress vascular endothelial precursor cell differentiation and/or endothelial precursor differentiation from stem cells and/or a substance that promotes vascularization as an active ingredient. The present invention also provides a... Agent: Law Office Of Michael A. Sanzo, LLC

20080025963 - Compositions and methods for the treatment of cns injuries: The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury. The method includes administering a therapeutically effective amount of glycosaminoglycan degrading enzyme. The glycosaminoglycan degrading enzyme may be dermatan sulfate or chondroitin sulfate degrading enzymes. The central nervous system contusion injury... Agent: Pepper Hamilton LLP

20080025964 - Modified ribonucleases: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in... Agent: Casimir Jones, S.c.

20080025965 - Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein levels: The invention features methods and compositions for reducing the serum C-reactive protein (CRP) level in a patient in need thereof, and for treating diseases and conditions associated with an increased serum CRP level. The invention also features methods and compositions for treating a patient diagnosed with, or at risk of... Agent: Clark & Elbing LLP

20080025973 - Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders: Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular... Agent: Alcon

20080025967 - Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in preventing and/or treating proliferative diseases caus: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080025968 - Methods and agents for immune modulation and methods for identifying immune modulators: Methods and agents for immune modulation and methods for identifying putative immune modulators are provided.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080025972 - Treating sex steriod responsive disorders: Sex steroid potentiated disorders including, prostate cancer and breast cancer, in a patient in need of treatment thereof, are treated with an amount of nitric oxide donating compound and/or nitrosoglutathione reductase inhibitor and/or cysteine binder different from that provided by nitric oxide donating compound effective to inhibit activation of steroid... Agent: Bacon & Thomas, PLLC

20080025969 - Treatment of neurodegenerative diseases by the use of gpr49: The invention relates to the use of a GPR49-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby s the GPR49-interacting molecule is preferably an inhibitor of GPR49 and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore... Agent: Clark & Elbing LLP

20080025974 - Human receptor proteins; related reagents and methods: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080025971 - Humanized anti-beta7 antagonists and uses therefor: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.... Agent: Genentech, Inc.

20080025970 - Treatment of atherosclerosis: Inhibitors of the adhesion of monocytes to oxidised low density lipoprotein or other lipid raft ligand for the therapy or prophylaxis of a condition involving monocyte adhesion to oxidised LDL or other lipid raft ligand, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis or glomerulonephritis. An assay for identifying such inhibitors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080025977 - Cytotoxicity mediation of cells evidencing surface expression of cd59: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20080025975 - Humanized antibodies against cd3: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific... Agent: Townsend And Townsend And Crew LLP

20080025976 - Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080025978 - High affinity ligand for p75 neurotrophin receptor: The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the protein and a vector containing the nucleic acid molecule. The present invention further provides... Agent: Hoffmann & Baron, LLP

20080025979 - Substance specific to human pd-1: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein... Agent: Sughrue-265550

20080025980 - Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.... Agent: Winston & Strawn LLP Patent Department

20080025981 - Cancer-linked genes as targets for chemotherapy: Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with methods for assaying for potential antitumor agents based on their modulation of the expression of these cancer-related genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions,... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080025983 - Methods of screening based on the egf receptor crystal structure: This invention relates to the structure of members of the epidermal growth factor (EGF) receptor family and to receptor/ligand interactions. In particular, it relates to the field of using the EGF receptor family structure to select and screen for compounds that inhibit the formation of active receptor dimers.... Agent: Foley And Lardner LLP Suite 500

20080025982 - Uses of sperm membrane protein obf: The present invention yielded unique monoclonal antibodies that reacted specifically only to sperms after acrosome reaction, and the antigens (OBFs) recognized by the antibodies were identified. The antibodies were found to inhibit fusion between mouse sperms and eggs. Furthermore, OBF gene-knockout mice were created and analyzed to clarify the in... Agent: Fish & Richardson PC

20080025984 - Combination therapy comprising cloretazine: This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. This invention also provides a method for inhibiting tumor cell growth comprising contacting the tumor cell with... Agent: Law Offices Of Albert Wai-kit Chan

20080025985 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Houston Eliseeva LLP - Ru

20080025986 - Methods of treating tnf-mediated disorders: The present invention provides methods of treating TNF-α-mediated disorders, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone or a pirfenidone analog and a second therapeutic agent that reduces TNF-α synthesis or that reduces TNF-α binding to a TNF receptor. The present invention further... Agent: Knobbe Martens Olson & Bear LLP

20080025987 - Release of bmp, bioactive agents and/or cells via a pump into a carrier matrix: A pump to deliver bone-growth factors to a carrier matrix within a patient. Pump can be internal or external. With external pumps, additional amounts of the same growth factor may be added, or the bioactive agent may be changed during the course of treatment. An external pump permits the use... Agent: Fox Rothschild, LLP

20080025988 - Monoclonal antibody and use thereof: p

20080025989 - Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical... Agent: Seattle Genetics, Inc.

20080025990 - Fully human antibodies directed against the human insulin-like growth factor-1 receptor: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the... Agent: Lucas & Mercanti, LLP

20080025992 - Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy: Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy.... Agent: Bozicevic, Field & Francis LLP

20080025991 - Use of aromatase inhibitors for treatment of ectopic pregnancy: Following a diagnosis of ectopic pregnancy, at least one aromatase inhibitor, is administered to a patient, either alone or in combination with other aromatase inhibitors or therapeutic agents or as an adjuvant to conservative surgical treatment, such as laparoscopy, to prevent the establishment and/or continuation of the ectopic pregnancy. In... Agent: Rohm & Monsanto

20080025993 - Method for refolding neisserial nspa protein: The present invention provides an isolated refolded NspA protein, and a method of preparing it.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080025994 - Methods and compositions for the treatment of pancreatitis: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.... Agent: Allergan, Inc.

20080025995 - Cross-placenta delivery system: The invention is directed to chimeral fusion proteins having an IgG1 antibody Fc portion and a lysosomal storage enzyme, particularly a Fc-GUS fusion protein useful in treating Sly's disease in an embryo or fetus. The invention is also directed to methods of treating in born errors of metabolism, particularly Sly's... Agent: Blackwell Sanders LLP

20080025996 - Methods and compositions comprising polycationic compounds: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.... Agent: Mark B. Wilson Fulbright & Jaworski L.L.P.

20080025997 - Cysteine-rich region of respiratory syncytial virus and methods of use therefor: The invention features methods and compositions featuring an RSV Glycoprotein fragment for modulating an immune response in a subject.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20080025998 - Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequence of chilamydia: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080025999 - Yersinia species compositions: A method of protecting an animal from infections with pathogens originating from Yersinia comprising administering an isolated or recombinant YscF protein to the animal is disclosed. The isolated or recombinant YscF protein may be administered as a vaccine. An isolated or recombinant YscF protein capable of conferring protection to an... Agent: Traskbritt, PC

20080026000 - Hapten-carrier conjugates for treating and preventing nicotine addiction: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates... Agent: Foley And Lardner LLP Suite 500

20080026001 - Pharmaceutical composition from natural materials for regulating immunity, its preparation method and use: The present invention relates to a new pharmaceutical composition from natural materials belonging in traditional Chinese medicine and to its preparation method. Said new pharmaceutical composition comprises Astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf. At first, astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf are... Agent: Andrews Kurth LLP Intellectual Property Department

20080026002 - Regimens for immunisation with meningococcal conjugates: Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.... Agent: Novartis Vaccines And Diagnostics Inc.

20080026003 - Methods for inhibiting pain: The invention provides methods for the treatment or prevention of pain. The invention also provides screening methods for determining whether a compound inhibits IL-1β activity in the central nervous system of a mammal.... Agent: Clark & Elbing LLP

20080026004 - Membrane virus host range mutations and their uses as vaccine substrates: The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines.... Agent: David L Parker Fulbright & Jaworski

20080026005 - Multicopy-integration of heterologous genes and expression in methylobacterium: The integration of genes into methylobacterium, such as M. extorquens ATCC 55366 is disclosed, using a transposon system, preferably the mini-Tn7 transposon system, and under the control of a promoter, such as the strong methanol dehydrogenase promoter (PmxaF). Multicopy integration of genes of interest is also disclosed. The unique and... Agent: Cassan Maclean

20080026006 - Pharmaceutical composition useful for vaccines: A pharmaceutical composition including at least a mixture of at least one oil, at least one surfactant and an aqueous phase, itself including at least one active substance, the pharmaceutical composition not being in the form of an emulsion, but in the form of an oily isotrope.... Agent: Ip Group Of Dla Piper US LLP

20080026007 - Potentiation of the immune response: A method for stimulating proliferation of T-cells containing cytoplasmic post-prolyl dipeptidase activity; the method, in one aspect, involves contacting the T-cells with an organic compound at a concentration below 10−8M, wherein the compound is characterized in that: (a) it is capable of crossing the membrane of T-cells to enter the... Agent: Choate, Hall & Stewart LLP

20080026008 - Bacteriophage dna vaccine vector: Bacteriophages are used as a DNA delivery system for a vaccine against pathogens where glycosylation is critical to immunity.... Agent: Thomas A. O'rourke Bodner & O'rourke

20080026009 - Borrelia burgdorferi bacterin: A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080026010 - Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination: The present invention relates to a malaria vaccine for administration to a host comprising an attenuated malarial parasite with a gene which has been rendered non-functional, wherein the gene, when present in naturally occurring form, encodes a protein necessary for continued in vivo survival and proliferation of the parasite and... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080026011 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20080026012 - Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex: The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in... Agent: Nixon & Vanderhye, PC

20080026013 - Compositions containing quaternary ammonium compounds: This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which... Agent: Young & Thompson

20080026014 - Nasal stick for the application of medicaments and skin care substances: A stick for the topical or transmucosal application of a skin care or active agent onto and via the nasal mucosa, respectively, is provided, wherein the stick material contains a composition of at least one carrier substance and at least one skin care or active agent, which is capable of... Agent: Harness, Dickey & Pierce, P.L.C

20080026015 - Thermochromic compositions for skin applicaion: Thermochromatic dyes may be added to compositions to be applied to skin in order to indicate where the composition is applied. After application to the skin the composition will turn from colored to colorless in a short period of time as its temperature rises in response to the curing reaction... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20080026018 - Administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities: At least one compound selected from among coumarin and/or derivative thereof, butylated hydroxyanisole, ethoxyquine and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents that slow hair loss and/or promote... Agent: Buchanan, Ingersoll & Rooney PC

20080026019 - Administration of ellagic acid for the treatment of canities: At least one compound selected from among ellagic acid, its salts, its metal complexes, its monoether or polyether, monoacylated or polyacylated derivatives and its carbonate or carbamate derivatives deriving from hydroxyl groups and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative... Agent: Buchanan, Ingersoll & Rooney PC

20080026016 - Aqueous dispersions of low-water solubility or water-insoluble active substances and dry powders produced therefrom: The present invention relates to aqueous dispersions and dry powders prepared therefrom, comprising at least one active substance which is sparingly soluble, or insoluble, in water and rice starch as protective colloid.... Agent: Connolly Bove Lodge & Hutz, LLP

20080026020 - Cosmetic composition combining a c-glycoside derivative and an associative polymer: The present invention relates to a cosmetic and/or pharmaceutical composition, especially a dermatological composition, comprising, in a physiologically acceptable medium containing an aqueous medium, at least one C-glycoside derivative and at least one associative polymer.... Agent: Oliff & Berridge, PLC

20080026021 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080026017 - Novel dipeptides incorporating selenoamino acids with enhanced bioavailability- synthesis, pharmaceutical and cosmeceutical applications thereof: Disclosed is a novel synthetic method for isomeric peptides through an appropriate linkage of L-selenomethionine or Se-Methyl-L-selenocysteine with L-glutamic acid. The novel synthetic method produces isomeric peptides of L-selenomethionine or Se-Methyl-L-selenocysteine that exhibit (i) enhanced water solubility; (ii) enhanced rate of dissolution in water; (iii) enhanced bioavailability; (iv) excellent vascular... Agent: Sabinsa Corporation

20080026022 - Process for the preparation of stable polymer concentrates: Process for preparing stable polymer concentrates, wherein acryloyldimethyltaurine and/or acryloyldimethyltaurate are free-radically polymerized with at least one further component in the presence of a polymerization medium, a higher-boiling solvent or solvent mixture is added to the resulting reaction product or reaction mixture, and the lower-boiling polymerization medium is removed, optionally... Agent: Clariant Corporation Intellectual Property Department

20080026023 - Textile material for management of skin health complications associated with skin folds, and its method of use: A textile material for management of skin health complications associated with skin folds includes a disposable textile of selected dimensions, impregnated with a selected concentration of an antimicrobial silver complex. The disposable textile is designed to be placed within a skin fold for management of skin health complications associated therewith.... Agent: Coloplast Corp. I.p. Department, U.s. Operations

20080026024 - Insect pest behavioral disturbance inducer, functional fiber, functional fabric and functional fiber product: The invention is an insect pest behavioral disturbance inducer which comprises an organic ester compound having a vapor pressure of 10−3 Pa (25° C.) order or less as an active ingredient, a functional fiber and a functional fabric, which hold aforementioned insect pest behavioral disturbance inducer, and a functional fiber... Agent: Sughrue-265550

20080026025 - Broad spectrum antimicrobial purification materials and methods for purifying fluids: Purification materials with broad spectrum antimicrobial properties and methods and devices for fluid treatment utilizing said materials are provided. The purification materials include biguanide hydrates and bases. A particular composition includes chlorhexidine dihydrate with the chemical formula (C22H30N10Cl2.1.3 H2O), which is useful in water purification applications.... Agent: Sutherland Asbill & Brennan LLP

20080026028 - Antimicrobial silver halide composition: This invention relates to a composition comprising at least 50% water, silver halide particles and a hydrophilic polymer, wherein the composition does not substantially gel or solidify at 25 degrees C.; is substantially free of organic solvents; and exhibits antimicrobial activity upon drying. The composition may further comprise a hydrophobic... Agent: Andrew J. Anderson Patent Legal Staff

20080026027 - Hybrid anti-fouling coating compositions and methods for preventing the fouling of surfaces subjected to a marine environment: The present invention relates to a coating composition including a sol-gel matrix and a dendrimeric organochalcogeno derivative and a system including the coating composition and a substrate. The present invention also relates to a method of preventing fouling of surfaces subjected to a marine environment.... Agent: Nixon Peabody LLP - Patent Group

20080026026 - Removable antimicrobial coating compositions and methods of use: This invention relates to a method for controlling microorganisms comprising coating a surface with a removable, antimicrobial film-forming composition.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080026029 - Energy-activated compositions for controlled sustained release of a gas: A composition for energy-controlled generation and release of at least one gas, which includes an energy-activated catalyst capable of being activated by electromagnetic energy, and a solid or a liquid containing anions capable of being oxidized by the activated catalyst or reacted with species generated during activation of the catalyst... Agent: Senniger Powers

20080026032 - Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use: Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated... Agent: Daniel J Swirsky

20080026030 - Corneal epithelial sheet and process for producing the same: A corneal epithelial sheet having a cell layer similar to the anterior epithelium of cornea. A corneal epithelial sheet is obtained through the step (a) of separately preparing a first cell being a self cell and a second cell whose origin is different from that of the first cell, the... Agent: Kratz, Quintos & Hanson, LLP

20080026031 - Implantable polymeric device for sustained release of buprenorphine: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric... Agent: Morrison & Foerster LLP

20080026033 - Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis: The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.... Agent: Howrey LLP

20080026034 - Therapeutic agent elution control process: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20080026035 - Method of treating atrophic vaginitis: The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.... Agent: Baker Botts L.L.P.

20080026036 - Method of feeding a ruminant: A method of feeding ruminants, the method including feeding a ruminant a fluid animal feed during a feeding period, the fluid animal feed including an animal feed component and the ruminant consuming greater than about 1.25 pounds of the animal feed component per day, based on the dry weight of... Agent: Law Office Of Phillip F. Fox

20080026037 - Compositions comprising strontium and vitamin d and uses thereof: The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080026038 - No laxation, low flatulence bulking system: A no-laxation, low flatulence bulking system and a method for preparation of same is disclosed. Gelatin, pectins and gellan gum are combined to form a dry-blended mixture. A second set of ingredients comprising at least erithritol is combined. A first liquid mixture comprising modified polydextrose and water is formed. The... Agent: Fulbright & Jaworski L.l.p

20080026040 - Active agent-releasing dosage forms: The present invention provides pharmaceutical compositions. In one aspect, a pharmaceutical composition is provided having a plurality of polymeric film layers heat sealed together as a multilayer structure and having an active agent dispersed within the multilayer structure. The multilayer structure is configured to release the active agent upon administration... Agent: Hewlett Packard Company

20080026039 - Benzoyl peroxide pads and formulations therefor: Pharmaceutical delivery systems suitable for topical administration including benzoyl peroxide. In a particular aspect, these pharmaceutical delivery systems comprise at least one pad and a drug composition comprising benzoyl peroxide absorbed onto the pad. These compositions are used for topical medical applications, particularly to treat various skin disorders.... Agent: Nath & Associates

20080026041 - Non-woven media incorporating ultrafine or nanosize powders: The invention is a fibrous structure for fluid streams that is a mixture of nano alumina fibers and second fibers arranged in a matrix to create asymmetrical pores and to which fine, ultrafine, or nanosize particles such as powdered activated carbon are attached without the use of binders. The fibrous... Agent: Cohen & Grigsby, P.C.

20080026042 - Preoperative treatment of post operative pain: A method of treating postoperative pain in a patient undergoing a surgery id described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent... Agent: Darby & Darby P.C.

20080026043 - Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer: The invention relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer and is anchored in the backing layer by siliconization.... Agent: Cathy R. Moore Propat

20080026045 - Combination chemotherapy comprising a gemcitabine and a liposomal platium complex: The present invention relates to methods for treating cancer comprising administering a combination of gemcitabine and a liposomal platinum complex, pharmaceutical compositions comprising gemcitabine and a liposomal platinum complex, and kits comprising unit dosage forms of gemcitabine and a liposomal platinum complex.... Agent: Jones Day

20080026044 - Combination chemotherapy comprising capecitabine and a liposomal platinum complex: The present invention relates to methods for treating cancer comprising administering a combination of capecitabine and a liposomal platinum complex, pharmaceutical compositions comprising capecitabine and a liposomal platinum complex, and kits comprising unit dosage forms of capecitabine and a liposomal platinum complex.... Agent: Jones Day

20080026046 - Stable aqueous g-csf conatining compositions: The invention relates to highly stable aqueous G-CSF-containing compositions that contain succinate and/or tartrate as the buffer substances. The invention further concerns lyophilisates and powders that are obtainable from such compositions, and to pharmaceutical kits containing such lyophilisates and powders.... Agent: Catalyst Law Group, Apc

20080026047 - Cancer detection reagents and uses in pathology and diagnostics and cancer cell death: Cancer detection reagents have been identified through comparison of cancer mRNAs with the transcriptome of healthy cells. These cancer detection reagents may be used for a variety of purposes including diagnostics and targeted destruction of cancer cells. In diagnostic applications, peripheral blood or other tissue samples from a subject may... Agent: Baker Botts L.L.P. Patent Department

20080026049 - Liposomal compositions for parenteral delivery of agents: The invention provides methods and compositions for loading an agent onto a liposome for parenteral delivery. The methods are suitable for the loading of poorly soluble agents onto liposomes.... Agent: Bereskin And Parr

20080026048 - Reovirus for the treatment of cellular proliferative disorders: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the... Agent: Fish & Richardson P.C.

20080026050 - Solid dose formulations of a thrombin receptor antagonist: t

20080026051 - Pharmaceutical form having a two-layer separating layer: A pharmaceutical form, contains an active compound-containing core, which is covered with a coating layer of a gastric juice-resistant, intestinal juice-soluble (meth)acrylate copolymer, a separating layer situated between said core and said coating layer, the separating layer containing a film-forming water-soluble polymer, wherein the separating layer contains at least two... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080026052 - Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats: The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.... Agent: Bell, Boyd & Lloyd, LLP

20080026053 - Capsule containing granular pharmaceutical compositions: A capsule for oral administration to a human subject. The capsule comprises at least two different pharmaceutical compositions in granular form. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20080026054 - Novel anelgesic combination: The invention discloses a method of administering a pharmaceutical combination comprising an NSAID and a slow release tramadol to a mammal in need of thereof. This invention further discloses an analgesic combination comprising an NSIAD and a slow release tramadol for treating pain and pain related conditions.... Agent: Ramesh Sesha

20080026055 - Chewable tablet containing phenylephrine: A chewable pharmaceutical composition comprising phenylephrine, artificial sweetener, and a substantially aldehyde-free matrix is provided. The composition has phenylephrine stability suitable for a typical commercial product with a two year shelf life. A method of manufacture of the composition and a method of use are also provided.... Agent: Wyeth Patent Law Group

20080026056 - Antibiotic-based pharmaceutical formulation in microcapsular form: c

20080026058 - Methods for treating and preventing mucositis: Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract... Agent: Jones Day

20080026057 - Process for the preparation of a solid, orally administrable pharmaceutical composition: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, the pharmaceutical composition resulting from this process, and its use for the prophylaxis and/or treatment of thromboembolic diseases.... Agent: Jeffrey M. Greenman

20080026059 - Methods of reducing degradant formation in pharmaceutical compositions of varenicline: The invention relates to methods for reducing degradant formation in pharmaceutical dosage forms of varenicline, which are useful for aiding smoking cessation and which have good storage stability. In particular, the present invention relates to methods for preparing formulations of varenicline wherein the dosage forms that are produced therefrom generate... Agent: Pfizer Inc Steve T. Zelson

20080026060 - Controlled-release pharmaceutical tablets: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080026061 - Crystalline n-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide: Provided herein are polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide and pharmaceutical compositions thereof. Also provided are methods of treatment of endothelin-mediated disorders by administering a polymorph N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide or pharmaceutical compositions thereof.... Agent: Jones Day

20080026062 - Pharmaceutical compositions including nano-sized active agent: The present invention is directed to a particulate pharmaceutical composition. The particulate pharmaceutical composition can comprise a water-soluble or partially water-soluble polymer matrix; and a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insoluble dispersed in the water-soluble or partially water-soluble polymer matrix. The particulate pharmaceutical... Agent: Hewlett Packard Company

20080026064 - Cell-polymer fiber compositions and uses thereof: The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-β-1→4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving... Agent: Jones Day

20080026063 - Composition containing reduced coenzyme q10 and production method thereof: The present invention provides a particulate composition wherein an oil component containing reduced coenzyme Q10 is polydispersed forming a domain in a matrix containing a water-soluble excipient, which simultaneously shows high oxidative stability and high oral absorbability, a production method thereof, and a stabilizing method thereof. It also provides a... Agent: Sughrue Mion, PLLC

20080026066 - Liquids containing suspended glass particles: Present proposals to use perfluorocarbons as a medium to suspend glass particles presents the problem of aggregation of the particles within the suspending medium. Overcoming this problem requires careful particle sizing and density matching techniques. An additional disadvantage of the large scale use of perfluorocarbons is their contribution to global... Agent: Brooks Kushman P.C./fgtl

20080026069 - Particles: Particles and related methods are disclosed.... Agent: Fish & Richardson PC

20080026065 - Powdered compositions of sensitive active materials in an at least partially amorphous state: The invention provides a powdered formulation which is a freeze-dried mixture of a sensitive active material and an excipient containing: 0.1-50% by wt of the sensitive active material, 50-99.99% by wt of the excipient, wherein at least 0.1% by wt of the mixture is an amorphous state; the formulation has... Agent: Hoffmann & Baron, LLP

20080026067 - Method for increasing specific surface area of slightly soluble drug: The preparation method of the powder of which dissolution rate improves is characterized by including of the process that slightly soluble drug having acidic group (e.g., 3-(5-{2-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]ethoxy}-3,4-dihydronaphthalen-1-yl)propanoic acid etc.) is made to metal salt solution and is neutralized to precipitate. By the method of the present invention, since a powder... Agent: Sughrue-265550

20080026070 - Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications: e

20080026068 - Pulmonary delivery of spherical insulin microparticles: Compositions of spherical insulin particles having improved pulmonary application potentials and methods of forming and using these compositions are disclosed in the present application. In one clinical trial with 30 healthy male human subjects, no coughing was observed upon a single pulmonary administration of the spherical insulin particles at an... Agent: Baxter Healthcare Corporation

20080026071 - Microparticles for delivery of heterologous nucleic acids: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. Also provided are microparticles... Agent: Lee, Helen Novartis Vaccines And Diagnostics, Inc.

20080026072 - Antimicrobial carbohydrates and methods of using same: Compositions useful for inhibiting the growth of bacteria, including bacteria that can cause gastric ulcers, are provided. In addition, transgenic organism that can produce such compositions are provided. Methods of using the compositions to treat or prevent gastric ulcers in a subject, including a human subject, also are provided.... Agent: Dla Piper US LLP

20080026073 - Method and composition for lithium additive in treatment of glutamate toxicity: Treatment of glutamate toxicity is accomplished using Lithium or a composition of Lithium and a botanical extract. The composition is administered using conventional techniques to increase the survival of ganglion cells exposed to glutamate toxicity resulting from ischemic events. In exemplary embodiments, the botanical extract is St. Johns Wort, Tian... Agent: Felix L. Fischer, Attorney At Law

20080026074 - Method of short term skin wrinkles correction using strontium divalent ion: A method for the treatment of skin damage using strontium divalent ion in a dermatologically acceptable carrier is provided, usually an essential oil distillate. The compositions are applied topically to improve appearance of skin damaged by sun or by natural aging. The compositions may additionally include antioxidant molecules such as... Agent: Hannah Sivak

20080026075 - Constitutional function-improving agents: Health function-improving agents, such as an immunological function-improving agent, an antioxidation function-improving agent, a exercise function-improving agent and a liver function-improving agent, comprising, as an effective ingredient, a δ-amino acid, a derivative thereof or a salt thereof... Agent: Sughrue-265550

20080026076 - Quercetin supplementation to treat hypertension: A nutritional supplement for improving cardiovascular health via aiding in preventing, slowing the progression of and/or treating hypertension, the supplement comprising quercetin; and a method for aiding in preventing, slowing the progression of and/or treating hypertension are described.... Agent: Needle & Rosenberg, P.C.

20080026077 - Methods and compositions of gene delivery agents for systemic and local therapy: A method is provided for the delivery of a therapeutic to epithelial cells through the use of a bile acid conjugated to a peptide, the peptide being ionically charged at physiological pH. The complex is well suited for oral and other forms of therapeutic administration of therapeutic drugs known in... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080026078 - Nasal composition: A nasal spray solution for use as a nasal spray and methods of using the solution are disclosed. The nasal spray solution moisturizes nasal passages and alleviates nasal dryness. The solution includes a hypotonic saline solution, wherein the saline solution is hypotonic with respect to cells of the nasal mucosa... Agent: Hahn Loeser & Parks, LLP

20080026079 - Calcium aluminosilicate pharmaceutical: A composition and method of treating symptoms of diarrhea that utilize administering an effective amount of an isolated calcium aluminosilicate anti-diarrheal (“CASAD”), wherein the isolated CASAD is substantially free from T4-dioxin and toxic heavy metal contamination, waiting a period of time; and repeating the administration of the composition until the... Agent: Jackson Walker LLP

20080026080 - Method for manufacturing calcium gluconolactate compositions processes and uses: A method to manufacture calcium gluconolactate as a single molecule, compositions formed thereby, and uses therefor are disclosed and described. In one embodiment, a method of manufacturing calcium gluconolactate by reacting a gluconic acid reaction or an equivalent thereof, such as glucono delta lactone with lactic acid in the presence... Agent: Thorpe North & Western, LLP.

20080026081 - Methods of treatment using (+)-isopropyl 2-ethoxyethyl-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate: The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents.... Agent: Millen, White, Zelano & Branigan

20080026082 - Erectyle disfunction phyto-nutraceutical synergistic composition: A Phytoceutical composition for the prevention and treatment of erectile dysfunction is provided. A specific combination of extracts of plants and nutraceuticals is based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel

20080026084 - Method and composition for management of weight and blood sugar: A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay. A composition is described... Agent: Ward And Smith, P.A.

20080026083 - Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae: The invention comprises compositions and methods for the treatment or prophylaxis of a microbial, fungal, or mold infection in an animal, comprising the administration of a composition derived from the essential oil of a Myrtaceae plant, wherein at least about 85% of the monoterpene content of the oil has been... Agent: Rader, Fishman & Grauer PLLC

20080026085 - Herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis: The present invention relates to a herbal mixture extract of Rehmanniae Radix Preparata and Acanthopanacis Cortex and a composition comprising the same for the prevention and treatment of osteoporosis. The herbal mixture extract of the present invention enhances the expression of osteoprotegerin (OPG) in osteoblasts and effectively inhibits the generation... Agent: Joseph Hyosuk Kim, Ph.d. Jhk Law

20080026086 - Synergistic neuroprotective, combinations of flavanols, hydroxystilbenes, flavanones, flavones, flavonols, proanthocyanidins and anthocyanidins: A synthetic composition is provided comprising (a) one or more compounds selected from the group consisting of flavanols and hydroxystilbenes; and (b) one or more compounds selected from the group consisting of flavanones, flavones, flavonols, proanthocyanidins and anthocyanidins. Also provided is a method of reducing neuronal degeneration in an individual... Agent: Unilever Intellectual Property Group

20080026087 - Litchi sinensis extracts containing oligomeric proanthocyanidins and processes of making thereof: A botanic extract of Litchi sinensis containing, based on active substance content, at least 15% by weight of an oligomeric proanthocyanidin of the OPC A2 type is disclosed. Processes of making such extracts containing at least 15% by weight of OPC A2 are also disclosed.... Agent: Cognis Corporation Patent Department

20080026088 - Reduced isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080019907 - Optical imaging contrast agents: The invention provides contrast agents for optical imaging of vulnerable atherosclerotic plaque in patients. The contrast agents may be used in diagnosis of vulnerable atherosclerotic plaque, for follow up of progress in disease development, for follow up of treatment of vulnerable atherosclerotic plaque and for surgical guidance. Further, the invention... Agent: Ge Healthcare, Inc.

20080019909 - Modulation of programmed necrosis: Methods related to modulating programmed necrosis are described. The methods relate to modulation of proteins involved in programmed necrosis, e.g., tumor necrosis factor receptor (2) (TNFR-2), tumor necrosis factor receptor (1) (TNFR-1), and receptor-interacting protein (RIP).... Agent: Fish & Richardson P.C.

20080019923 - Gas bubble-generating agent: This invention provides a gas bubble-generating agent that can be used as a contrast medium or a blocking agent in vivo. Such gas bubble-generating agent is produced by a method for producing a gas bubble-generating agent comprising the following steps of: (a) preparing a mixed solution of an amphiphilic substance,... Agent: Mattingly, Stanger, Malur & Brundidge, P.C.

20080019932 - Color cosmetic compositions: A color cosmetic composition comprising at least one silicone film forming polymer, at least one pigment, and at least one dispersant that aids in dispersion of the pigment and silicone film forming polymer in the composition.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080019935 - Conditioning composition comprising silicone agent for ease-to-rinse feel and/or clean feel: Disclosed is a conditioning composition comprising by weight: (a) from about 0.1% to about 10% of a cationic surfactant; (b) from about 1% to about 15% of a high melting point fatty compound; (c) from about 0.01% to about 10% of a silicone agent comprising a silicone backbone, a hydrophilic... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080019939 - Conditioner formulation: Provided is a conditioning formulation, which preferably includes one or more bis-alkoxy-terminated glycol-functionalized aminosilicones, one or more non-functionalized aminosilicones, one or more fatty alcohols, one or more alkyl quaternary ammonium salts, and water. Also provided is a method of conditioning keratinous fibers (e.g., hair), which includes applying to the keratinous... Agent: Leydig Voit & Mayer, Ltd

20080019936 - Multi-purpose shave composition: This invention relates to the composition of a multi-purpose shaving composition; designed to work with electric shaving devices and manual razors.... Agent: Nikita Wilson

20080019941 - Methods, systems and reagents for scar reduction: The present invention is directed towards the use and delivery of a therapeutic method and agent to reduce and prevent excessive scarring resulting from cellular contraction and/or excess accumulation of extracellular matrix by inhibition and/or inducement of smooth muscle actin (SMA) and/or tissue growth factor beta (TGF-β) in a tissue,... Agent: Fox Rothschild, LLP

20080019944 - Methods and materials for providing cardiac cells: This document provides methods and materials relating to cardiac cells. For example, this document provides methods and materials that can be used to obtain cells having the ability to differentiate into cardiomyocytes. Such cells can be used to repair damaged heart tissue. For example, cells having the ability to differentiate... Agent: Fish & Richardson P.C.

20080019945 - Attenuation of cytomegalovirus virulence: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.... Agent: Johnathan Klein-evans

20080019948 - Process for producing engineered targeted t cell and medicine: A novel process for preparing tumor-specific T cells is disclosed. According to the invention, antitumor-active, tumor-specific T cells are prepared by transducing a TCR gene from a tumor-specific CTL into antitumor-active T cells that have been nonspecifically activated, thus enabling tumor-specific cellular immunotherapy to be carried out from even small... Agent: Birch Stewart Kolasch & Birch

20080019955 - Surface protection of exposed biological tissues: The invention relates to a biodegradable barrier network comprising at least two polypeptides, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create said biodegradable barrier network. The invention also relates to the use of said applicator... Agent: Merchant & Gould PC

20080019956 - Enzymatic prevention and control of biofilm: Described herein is a composition for removing biofilm from surfaces. The composition is an enzyme mixture having at least three enzymes and resulting in the removal of at least 40% biofilm from the surface.... Agent: Janet Kaiser Castaneda Genencor International, Inc.

20080019957 - Topically applied probucol-containing agent with protective and regenerative effect: A method of treating skin changes and conditions in human skin including applying a topical preparation that includes an active agent including probucol, a derivative of probucol or a combination of probucol and a derivative of probucol.... Agent: Joseph W. Holland Holland Law Office PLLC

20080019904 - System for manufacturing micro-sheres: System for manufacturing micro-spheres of a production fluid (23) containing a constituting material. The system comprises a reservoir (1) for holding a receiving fluid (11). There further is provided a jetting module (2) having at least one nozzle (21) for jetting the production fluid into the receiving fluid. The production... Agent: Philips Intellectual Property & Standards

20080019905 - Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection: The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer... Agent: Gtc Biotherapeutics, Inc, C/o Wolf, Greenfield & Sacks, P.C.

20080019906 - Methods and agents for preparing 18f-radiolabeled fluorinating agents: The present invention is directed to a method for preparing an anhydrous 18F-radiolabeled fluorinating agent by a nucleophilic reaction of a hydrated 18F-radiolabeled fluoride ion source with an unsaturated carrier compound; treating the 18F-radiolabeled carrier compound to produce a non-aqueous mixture of the 18F-radiolabeled carrier compound in a solvent; and... Agent: Thompson Coburn, LLP

20080019908 - Novel amphiphilic substance, and drug delivery system and molecular imaging system using the same: The present invention provides a novel amphiphilic substance, a nanoparticle using the novel amphiphilic substance, which can be used as a nanocarrier having high biocompatibility, a drug delivery system and a probe useful for the system, and, a molecular imaging system and a probe useful for the system. An amphiphilic... Agent: Rader Fishman & Grauer PLLC

20080019910 - Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors: Disclosed is a method for improving cancer therapy that relies on induction of apoptosis in malignant cells. It has been found that docking of protease inhibitors PAI-1 and TIMP-1 renders malignant cells expressing these inhibitors more sensitive to apoptosis, whereas non-malignant cells do not change their sensitivity to apoptosis induction.... Agent: Roberts, Mlotkowski & Hobbes

20080019913 - Enkepahlin analogs with improved bioavailability: Peptides having improved bioavailability, especially analogs of enkephalins, with biousian properties which have two conformations or two conformation ensembles with different solubility properties.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080019912 - Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective... Agent: Mckee, Voorhees & Sease, P.L.C

20080019911 - Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4: Angiopoietin like protein 4 is a novel circulating protein predominantly expressed in adipose tissue and liver. Several recent studies demonstrated that angiopoietin like protein 4 is the target gene of peroxisome proliferation activators, the agonists of which are widely used as the anti-diabetic and lipid-lowering drugs. The invention provides a... Agent: Cooper & Dunham, LLP

20080019916 - Methods and pharmaceuticals for treating muscle insulin resistance and related conditions: A method of screening compounds for the ability to increase capillary blood flow, the method comprising: (a) taking a first measurement of capillary blood flow in a subject; (b) administering a compound to said subject; (c) taking a second measurement of capillary blood flow in said subject, and (d) comparing... Agent: Nixon & Vanderhye, PC

20080019915 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20080019914 - Pesticidally active proteins and polynucleotides obtainable from paenibacillus species: The subject invention provides unique biological alternatives for pest control. More specifically, the present invention relates to novel pesticidal proteins, novel sources of pesticidal proteins, polynucleotides that encode such toxins, and to methods of using these toxins to control insects and other plant pests. The subject invention relates to the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080019917 - Compositions comprising cells and magnetic materials for targeted delivery: The present invention provides a method in which a formulation comprising cells and a magnetic material is administered to a subject and part of the body of said subject is subjected to a magnetic field, as well as a kit for use in this method. A medical device for use... Agent: Needle & Rosenberg, P.C.

20080019918 - Medicinal preparation: A pharmaceutical preparation has a ligand structure specifically recognizing a target site and an amphiphilic compound having a hydrophobic or amphiphilic group. The pharmaceutical preparation employs an amphiphilic compound of specific structure obtained by introducing a chained hydrophilic group with an appropriate flexibility, and thus becomes a fine particle suited... Agent: Kubovcik & Kubovcik

20080019919 - Method for optimizing cancer therapy by monitoring maturation of tumor associated vasculature by selenium: This invention provides a method for a method for optimizing the regimen for the administration of chemotherapeutic agents. The method comprises administration of a selenium compound to an individual, monitoring the modulation of tumor vessel maturation (TVM) to identify an optimal time for administration of a chemotherapeutic agent. This invention... Agent: Hodgson Russ LLP The Guaranty Building

20080019922 - Quinazoline derivatives, their preparation, their use, and medicaments comprising them: i

20080019920 - Neurotransmitter sensors and methods of using the same: Neurotransmitter biosensors are disclosed, including YbeJ-based glutamate binding biosensors, comprising a neurotransmitter binding domain conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon binding neurotransmitter. Such biosensors are useful for the detection of neurotransmitter concentrations in vivo and in culture.... Agent: Morgan Lewis & Bockius LLP

20080019921 - Uniform fluorescent microsphere with hydrophobic surfaces: Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material... Agent: Invitrogen Corporation C/o Intellevate

20080019925 - Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same: An edible product such as a unit dosage form of a pharmaceutically active substance includes a layer of a material that can receive and retain a high resolution microrelief that can convey information. The microrelief is themo-formable, preferably formed from an aqueous solution of HPMC and/or HPC plus a plasticizer... Agent: Edwards Angell Palmer & Dodge LLP

20080019924 - Non-toxic flakes for authentication of pharmaceutical articles: In one embodiment of the present invention, non-toxic inorganic flakes are used for identification and anticounterfeit protection of pharmaceutical articles, such as pills, tablets and capsules, having a core of a biologically active material and/or a biologically inert material. Non-toxic inorganic authentication flakes, either optically variable flakes or taggant flakes... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20080019927 - Compositions and methods for dermally treating neuropathy with minoxidil: The present invention is drawn to adhesive solidifying formulations containing minoxidil that can be used for treating neuropathies including diabetic neuropathy. The formulation can include an amount of minoxidil, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile... Agent: Thorpe North & Western, LLP.

20080019926 - Lung surfactant supplements: The invention relates to a method for improving the fluidity and/or the spreadability of the native lung surfactant in a human or animal in need of such treatment, wherein the human or animal is administered with a fluorocarbon composition. The invention further relates to therapeutic compositions comprising a fluorocarbon, optionally... Agent: Young & Thompson

20080019928 - Clear, two-phase, foam-forming aerosol hairstyling product: A hair care product is described, which consists of transparent, pressure-resistant aerosol packaging, a device for foaming a composition contained in the aerosol packaging, and a foaming composition of at least two clear liquid phases separated from each other. The composition contains water; at least 15 wt %, based on... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080019929 - Micro-particulate organic uv absorber composition: Disclosed is a topically applicable water-in-oil (w/o) or water-in-silicone (w/Si) formulation comprising: (a) at least one aqueous phase; (b) at least one fatty phase; (c) an effective UV-photoprotecting composition comprising (c1) 20% to 99% of at least one insoluble micronized organic UV-screening active with a mean particle size ranging from... Agent: Ciba Specialty Chemicals Corporation Patent Department

20080019930 - Dibenzoylmethane sunscreens photostabilized with arylalkyl amide or ester compounds: Improvedly effective and photostable sunscreen compositions combine a dibenzoylmethane screening agent and a specific arylalkyl amide or ester compound of the following formulae (I), (II) or (III):... Agent: Buchanan, Ingersoll & Rooney PC

20080019931 - Method and composition for producing enhanced fingernails: A method for increasing the strength, thickness and surface smoothness of a finger nail composed primarily of keratin but also containing small amount of calcium.... Agent: Theodore Jay

20080019933 - Method of making-up dark skin: The present invention relates to a method of making-up dark skin, the method comprising the step consisting in applying to the skin a cosmetic composition comprising, in a cosmetically acceptable medium, at least one red interference pigment which, when the composition is applied to the skin, is capable of generating... Agent: Oliff & Berridge, PLC

20080019934 - Water-in-oil emusions for the treatment of keratin fibers, comprising at least one cyanoacrylate monomer and aqueous ammonia: The present disclosure relates to a water-in-oil emulsion which comprises an aqueous phase comprising at least one surfactant; at least one nitrogenous alkaline agent of the aqueous ammonia or amine type and an oily phase comprising at least one cyanoacrylate monomer. The water-in-oil emulsion of the present disclosure can make... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080019937 - Method of curl retention in hair and lashes: The invention relates to a method of retaining, enhancing or imparting curl in a keratinous material which comprises applying to the keratinous material a retention effective amount of a transglutaminase enzyme.... Agent: Karen A. Lowney Estee Lauder

20080019938 - Hair treatment composition comprising sugar lactone: A hair treatment composition for straightening hair. The composition comprises: i) 0.1 to 7.9 wt % of the total formulation of a sugar lactone; and ii) cationic surfactant of formula (1): [N(R1)(R2)(R3)(R4)]+(X)− in which R1, R2, R3, and R4 are independently selected from (a) an aliphatic group of from 1... Agent: Unilever Intellectual Property Group

20080019940 - Protein conjugates with a water-soluble biocompatible, biodegradable polymer: The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same.... Agent: Choate, Hall & Stewart LLP

20080019942 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as... Agent: Knobbe Martens Olson & Bear LLP

20080019943 - Broad spectrum immune and antiviral gene modulation by oral interferon: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.... Agent: Nixon & Vanderhye, PC

20080019946 - Integration-type low-dose radiation-inducible vector: An integration-type low-dose radiation-inducible viral vector comprising a DNA sequence comprising a p53 target gene promoter sequence and a therapeutic gene sequence. The vector of the present invention is useful for gene therapy.... Agent: Welsh & Katz, Ltd

20080019953 - Methods and compositions for correction of cardiac conduction disturbances: The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the... Agent: Bozicevic, Field & Francis LLP

20080019952 - Novel method for the preparation of embryoid bodies (ebs) and uses thereof: Provided are means and methods for producing embryoid bodies (EBs) from multi- or pluripotent cells. In particular, a method of generating embryoid bodies (EBs) is described comprising agitation of a liquid suspension culture of multi- or pluripotent cells in a container until generation of cell aggregates, optionally diluting the suspension,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080019954 - Lactic acid bacteria strains useful against urogenital pathogens and compositions containing same: The invention relates to a method for preventing or treating urogenital infections in females, which comprises administering a pharmaceutical preparation comprising, in combination with a suitable galenical carrier, a therapeutically effective amount of at least one lactic acid bacteria strain of the genus L. acidophilus, L. crispatus, L. gasseri, L.... Agent: Winston & Strawn LLP Patent Department

20080019947 - Microbial pesticide inhibiting the outbreak of plant disease damage: This invention is to provide microbial pesticides that can control plant disease damages by spraying the microbial pesticides, which contain filamentous fungus Verticillium lecanii having suppressant effect on the growth of plant pathogen, onto plants such as fruits and vegetables, and to provide soil borne improvement agents which contain filamentous... Agent: Alston & Bird LLP

20080019949 - Differentiation of stem cells from umbilical cord matrix into hepatocyte lineage cells: The invention relates to methods for differentiating umbilical cord matrix cells into hepatocyte-like cells and compositions and methods for using such hepatocyte-like cells.... Agent: Seed Intellectual Property Law Group PLLC

20080019951 - Method and apparatus for installation of dental implant: An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20080019950 - Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells: The present invention relates to a novel hepatocyte-like cell population derived from hBS cells and to the potential use of such heopatocyte-like cells in e.g. medical treatment, drug screening and toxicity testing. Furthermore, the invention relates to hepatoblast-like cells that may have suitable characteristics so that they can be used... Agent: Buchanan, Ingersoll & Rooney PC

20080019959 - Process for separating and determining the viral load in a pancreatin sample: Processes for separating an infectious viral load from a pancreatin sample and for quantitatively determining the viral load in a pancreatin sample are described herein.... Agent: Mayer Brown LLP

20080019958 - Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof: The present invention provides novel polynucleotides encoding MGAT3 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MGAT3 polypeptides to the diagnosis, treatment, and/or prevention... Agent: Louis J. Wille Bristol-myers Squibb Company

20080019963 - Antibodies, polypeptides and uses thereof: A method of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. An antibody that has the amino acid sequences i) to iii), the amino acid sequences iv) to vi), or the... Agent: Wolf Greenfield & Sacks, P.C.

20080019962 - Endotheliase-2 ligands: Proteins that bind to ET2, such as immunoglobulins that inhibit ET2 with high affinity and selectivity, are provided. The ET2 binding proteins can be used to treat a variety of disorders, including angiogenesis-associated disorders.... Agent: Fish & Richardson PC

20080019961 - Hedgehog signaling pathway antagonist cancer treatment: The present invention provides methods and compositions for treating tumorigenic cells (e.g., mammary progenitor cancer cells), with hedgehog signaling pathway antagonists (e.g., Cyclopamine or analogs thereof), as well as methods and compositions for screening hedgehog signaling pathway antagonists for their ability serve as anti-neoplastic agents capable of killing tumorigenic cells.... Agent: Casimir Jones, S.c.

20080019960 - Methods of treating viral disorders: Methods of treating viral disorders are disclosed.... Agent: Leydig Voit & Mayer, Ltd

20080019965 - Individualized anti-cancer antibodies: The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used... Agent: Mchale & Slavin, P.A.

20080019967 - Inflammatory mediator antagonists: The present invention relates to pharmaceutical compositions comprising a unit dose of at least 1 mg of an antibody to oncostatin M (OSM) and a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition comprises an antibody that blocks OSM from interacting with OSM receptor gp130.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080019966 - Monoclonal antibodies to hepatocyte growth factor: The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Townsend And Townsend And Crew, LLP

20080019964 - Use of certain drugs for treating nerve root injury: The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorders.... Agent: Fish & Richardson PC

20080019968 - Detection, prevention and treatment of breast cancer: The invention provides compositions and arrays of glycans for detecting, treating and monitoring breast cancer in a human or other mammal.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080019969 - Methods for preventing, postponing or improving the outcome of invasive spinal procedures: Methods for identifying subjects who could benefit therapeutically from administration of a targeted anti-inflammatory therapy (TAT) are provided. Subjects that are identified include those that are eligible, based on pre-determined criteria, for a spinal surgery procedure, such as a laminectomy or diskectomy. Methods of preventing such procedures or improving the... Agent: Fish & Richardson P.C.

20080019970 - Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures: Methods for identifying subjects who could benefit therapeutically from administration of a high specificity cytokine inhibitor are provided. Subjects that are identified include those that are eligible, based on pre-determined criteria, for a spinal device or fusion procedure, such as the implantation of a nucleus replacement device, an annular repair... Agent: Fish & Richardson P.C.

20080019971 - 36p6d5: secreted tumor antigen: Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary and pancreas.... Agent: Agensys C/o Morrison & Foerster LLP

20080019972 - Method for amplifying therapeutic vaccine activity: A method of amplifying activity of therapeutic vaccines including administering an effective amount of a composition including a compound that depletes or inhibits B lymphocytes to a patient sufficiently to amplify an immune reaction of T cytotoxic lymphocytes. The composition may be administered to a patient to augment the specific... Agent: Ip Group Of Dla Piper US LLP

20080019973 - Methods for treating ocular inflammation by neutralizing cxcl10 activity: The invention provides a method of reducing ocular inflammation in an individual susceptible to ocular inflammation. The method involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Also provided is a method for reducing spread of viral infection within ocular tissues of an individual... Agent: Mcdermott, Will & Emery

20080019974 - Humanized monoclonal antibodies to hepatocyte growth factor: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Townsend And Townsend And Crew, LLP

20080019975 - Novel regimens for treating diseases and disorders: Methods and materials are provided for induction-maintenance regimens of targeted anti-inflammatory therapies (TATs) for treatment of a variety of diseases and disorders. Preferred embodiments include administration of one or more TATs using an induction regimen comprising a lower dose per administration administered by a more invasive and/or more localized route,... Agent: Fish & Richardson P.C.

20080019976 - Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets... Agent: Lahive & Cockfield, LLP

20080019978 - Nitrogen-containing heterocyclic compounds and methods of use thereof: e

20080019977 - Prevention and treatment of retinal ischemia and edema: The present invention relates to methods of treating retinopathy, retinal ischemia and/or retinal edema comprising administering an integrin or integrin subunit antagonist, leukocyte adhesion-inducing cytokine antagonist or growth factor antagonist, a selectin antagonist or adhesion molecule antagonist.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080019979 - Herv-k antigens, antibodies, and methods: Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K+ cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking... Agent: Baker Botts, LLP

20080019980 - Viruses for the treatment of cellular proliferative disorders: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus,... Agent: Fish & Richardson P.C.

20080019981 - Viruses for the treatment of cellular proliferative disorders: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus,... Agent: Fish & Richardson P.C.

20080019982 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Houston Eliseeva LLP - Ru

20080019983 - Method of protecting against staphylococcal infection: A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection,... Agent: Rossi, Kimms & Mcdowell LLP.

20080019984 - Blood-brain barrier targeting antibodies: This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and the antibody directs delivery of the compound across the blood brain barrier (BBB). The invention... Agent: Quarles & Brady LLP

20080019986 - Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof: This invention provides a method of inhibiting the binding of a β-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding inhibiting amount of a compound capable of inhibiting binding of the β-sheet fibril to RAGE so as to thereby inhibit binding... Agent: John P. White, Esq. Cooper & Dunham LLP

20080019985 - Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region... Agent: Banner & Witcoff, Ltd.

20080019989 - Immunity adjuvant containing a complexed metal cation and vaccine containing same: The present invention relates to novel adjuvants for vaccine compositions and said compositions comprising at least one antigen, in particular an antigen of vital, bacterial or parasitic origin and at least one adjuvant. In particular, the subject of the invention is a composition comprising a fatty phase and a nonzero... Agent: Hunton & Williams LLP Intellectual Property Department

20080019987 - Methods of inducing il-10 production: The invention provides a method of inducing IL-10 production... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080019988 - Targeting of genetic vaccine vectors: This invention provides methods of obtaining reagents for increasing the specificity of genetic vaccines for a desired target cell or tissue type. The invention also provides delivery vehicles for use to improve genetic vaccine specificity for a target cell or tissue type.... Agent: Maxygen, Inc. Intellectual Property Department

20080019992 - Antigen mimotopes and vaccine against cancerous diseases: The present invention relates to a vaccine against cancerous diseases and antigen mimotopes associated with the high molecular weight melanoma associated antigen (HMW-MAA). The vaccines and antigen mimotopes are recognized immunologically by the monoclonal HMW-MAA antibody 225.28S and comprise at least one peptide with a length of 6 to 14... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080019991 - Carrier conjugates of tnf-peptides: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP and a particular peptide derived from a polypeptide from the TNF-superfamily linked thereto. The invention also provides a process for producing the modified VLP.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080019993 - Inhibition of tumour growth: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them... Agent: Crowell & Moring LLP Intellectual Property Group

20080019990 - Therapeutic binding agents against muc-1 antigen and methods for their use: The invention provides therapeutic compositions comprising binding agents that specifically bind to tumor-associated MUC-1 and reduce, reverse or prevent their effects in cancer. More particularly, the invention provides therapeutic compositions that comprise a binding agent that can specifically bind to an epitope that comprises both peptide and carbohydrate on such... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080019994 - Immunization against chlamydia infection: The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a polypeptide of a... Agent: Patrick J. Halloran, Ph.d.

20080019995 - Diagnostic assay for trypanosoma cruzi infection: A sensitive, multicomponent diagnostic test for infection with T. cruzi, the causative agent of Chagas disease, including methods of making and methods of use. Also provided is a method for screening T. cruzi polypeptides to identify antigenic polypeptides for inclusion as components of the diagnostic test, as well as compositions... Agent: Mueting, Raasch & Gebhardt, P.A.

20080019996 - Mushroom extracts having anticancer activity: The invention relates to a method for treatment of chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), prostate cancer and β-globin disorders such as sickle cell anemia and β-thalassemia, comprising administration of a mycelium extract from at least one higher Basidiomycetes medicinal mushroom selected from the group consisting of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080019997 - Therapeutic uses of dunaliella powder: A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crude Dunaliella powder, optionally together with an activator of nuclear... Agent: Gary M. Nath The Nath Law Group

20080019998 - Targeted gene delivery for dendritic cell vaccination: Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions,... Agent: Knobbe Martens Olson & Bear LLP

20080019999 - Method of vaccinating subjects receiving immune modulating therapy: The present invention relates to methods of vaccinating subjects receiving immune modulating therapy, such as soluble CTLA4 molecules, for treatment of immune system diseases mediated by T-cell interactions with B7-positive cells including, but not limited to, autoimmune diseases, immunoproliferative diseases, and immune disorders associated with graft transplantation.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080020000 - Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading: Pharmaceutical compositions, each consisting of a cell-permeable fusion protein conjugate of a polypeptidic cell-membrane transport moiety and a Clostridium botulinum C3 exotransferase unit, or a functional analog thereof, are provided. The compositions are useful to prevent or inhibit uncontrolled proliferation, spreading, and migration of a metastatic neoplastic cell of a... Agent: Birch Stewart Kolasch & Birch

20080020001 - Preparation of protective antigen: A polynucleotide sequence is provided, comprising: a nucleic acid sequence having at least 75% identity to SEQ ID NO: 1, wherein said nucleic acid sequence encodes recombinant Bacillus anthracis Protective Antigen (rPA); or a fragment of said nucleic acid sequence wherein said fragment encodes a fragment of recombinant Bacillus anthracis... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080020002 - Method of producing meningococcal meningitis vaccine for neisseria meningitidis sero types a,c,y, and w-135: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified,... Agent: Jeeri R. Reddy

20080020003 - Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same: The present invention relates to method for inducing bronchodilation in a patient in need thereof comprising (a) providing at least one dose of an inhalation mixture comprising a β2 agonist to said patient; and (b) delivering said inhalation mixture with an inhalation nebulizer, as well as dosage formulations comprising a... Agent: Wilson Sonsini Goodrich & Rosati

20080020005 - Alpha hydroxy acid sustained release formulation: An oil-in-water emulsion containing one or more alpha hydroxy acids in which the oil phase of the emulsion contains a high proportion of polar constituents. The emulsion, even at high concentrations of alpha hydroxy acid, is not irritating when applied to the skin.... Agent: Howard Eisenberg, Esq.

20080020004 - Hair-treatment agent comprising terpolymer of vinylpyrrolidone, methacrylamide and vinylimidazole and active ingredients and additives: A hair-treatment agent is described with a content of a combination of a terpolymer constructed from vinylpyrrolidone, methacrylamide and vinylimidazole, and at least one active ingredient or additive chosen from viscosity-modifying substances, haircare substances, hair-setting substances, silicone compounds, photoprotective substances, oils, waxes, preservatives, pigments, soluble dyes, particulate substances, and surfactants... Agent: Michael J. Striker

20080020007 - Liquid-containing film structure: The present invention describes a film structure which comprises a plurality of microcups and the microcups are filled with a liquid composition and top-sealed with a sealing layer which is hardened in situ. The liquid composition may be a display fluid or a pharmaceutical composition. The present invention is directed... Agent: Howrey LLP

20080020008 - Eutectic crystalline sugar alcohol and manufacturing method thereof: To provide an eutectic crystalline sugar alcohol representing a single melting peak obtained by differential scanning calorimetry, which does not show any one of problems of requiring the addition of a comparatively large amount of a seed crystal to be added for crystallization and a prolonged aging period of several... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080020006 - Stabilisation of colorants in cosmetic and dermatological preparations:

20080020009 - Fungicidal composition comprising nanometer sized oil particle and method of manufacturing the same: Disclosed are a fungicidal composition comprising oil, an emulsifier and water, and a method for preparing the same. The fungicidal composition is an oil-in-water (o/w) type emulsion that can be obtained by spraying the oil and emulsifier to ionized water. The oil is presented as particles with a particle diameter... Agent: Sughrue Mion, PLLC

20080020010 - Pyridinone diketo acids: inhibitors of hiv replication: A new class of diketo acids constructed on pyridinone scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as... Agent: Coleman Sudol Sapone, P.C.

20080020014 - Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders: The present invention is directed to implantable devices (e.g., drug-delivery stents) containing nuclear receptor ligands. The nuclear receptor ligands may be, inter alia, PPAR ligands or retinoids. The invention also provides for a method of treating or preventing vascular disorders (e.g., restenosis) and related disorders using the nuclear receptor ligand-containing... Agent: Squire, Sanders & Dempsey LLP

20080020012 - Collagen scaffolds, medical implants with same and methods of use: The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080020013 - Methods of manufacturing and modifying taxane coatings for implantable medical devices: This disclosure relates to endolumenal medical devices coated with a taxane therapeutic agent in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous paclitaxel, dihydrate paclitaxel, or combinations thereof that provide durable coatings that release paclitaxel over a desired period of time, which can be... Agent: Brinks Hofer Gilson & Lione/indy/cook

20080020011 - Therapeutic implant: The invention relates an implant, which comprises a biologically compatible substrate, to which at least one moiety is bound by a ligand, the moiety being one which specifically binds to and selectively immobilizes, at least one known target present in body fluid. The moiety traps the target and thus enables... Agent: Stites & Harbison PLLC

20080020015 - Bioactive wound dressings and implantable devices and methods of use: The present invention provides wound dressings, optionally surgically implantable, containing biodegradable, polymers and hydrogels having allogenic or autologous precursor cells, such as stem cells and progenitor cells dispersed within. Alternatively, the wound dressings can have conditioned medium obtained from the precursor cells dispersed within. The wound dressings promote tissue restoration... Agent: Dla Piper US LLP

20080020016 - Pharmaceutical compositions for sustained release delivery of peptides: The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a biocompatible, water-insoluble, biodegradable polymer and an effective amount of a therapeutic peptide covalently modified with one or more lipophilic or amphiphilic moieties, which... Agent: Cohen, Pontani, Lieberman & Pavane

20080020017 - Intraocular irrigating solution having improved flow characteristics: Improved intraocular irrigating solutions are described. The solutions have enhanced viscosities that reduce the risk of damage to intraocular tissues during intraocular surgical procedures by reducing the turbulence of the solutions and dampening the movement of tissue fragments and air bubbles. The solutions preferably also have modified surface tensions that... Agent: Alcon

20080020018 - Combination products: A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active ingredient, and at least some of the minicapsules containing a corticosteriod as another active ingredient.... Agent: Jacobson Holman PLLC

20080020021 - 5-hydroxysapogenin derivatives with anti-dementia activity: The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20080020020 - Beverage: e

20080020019 - Method of decreasing fat deposits and body weight in mammals and birds: A method is disclosed utilizing an optically pure eutomer of salbutamol for reducing body fat and/or body weight in mammals and birds. A food composition including the eutomer is also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20080020022 - Chewable co-enzyme q-10 capsule: The present invention is directed to compositions and methods of delivery of CoQ-10 encapsulated in a chewable soft gelatin capsule.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080020023 - Nonaqueous coating composition for elastomeric articles and articles containing the same: The invention described herein relates to a therapeutic, moisturizing coating composition for elastomeric articles which is applied directly onto the skin-contacting surface of the article as part of the manufacturing process. The coating composition is thermally stable and subsequently transfers when in contact with a skin surface to convert into... Agent: Kimberly C. Luna Patent Administrator

20080020024 - Fast dissolving orally consumable films: A consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, comprising at least one water soluble polymer, a taste masking effective amount of a sweetener, a mucosa-coating effective amount of a mucosa-coating agent and a pharmaceutically active agent having a sufficiently... Agent: Philip S. Johnson Johnson & Johnson

20080020025 - Composition for wound care and method of using same: This invention encompasses an expeditious method and composition for treating a wide variety of wounds and injuries by promoting the elevation of pH at the site of injury, enhancing the reduction or elimination of pain and scaring from the patho-physiological process of infection proliferation, and promoting enhanced wound care management... Agent: Snell & Wilmer L.L.P. (main)

20080020026 - Hemostatic compositions and methods for controlling bleeding: The invention provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions typically include an article containing cellulose, e.g., cotton gauze, and a polysaccharide covalently linked to the cellulose, or a polysaccharide ionically cross-linked and in association with the article. Methods of making and using... Agent: Fish & Richardson P.C.

20080020027 - Film-delivering rinse: Provided, among other things, is a method of treating or ameliorating an indication of mucosal or adjacent tissue comprising periodically applying to mucosa at or adjacent to disease affected tissue a rinse comprising: an effective amount of appropriate composition of herbal bioactive comprising active(s) of one or more of Sambucus... Agent: Law Offices Of Arthur E. Jackson

20080020028 - Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent: This invention relates to a tamper-resistant transdermal dosage form comprising an active agent, such as an opioid, or a pharmaceutically acceptable salt thereof, a free base of an adverse agent, such as an opioid antagonist, and a pharmaceutically acceptable salt of an adverse agent, such as an opioid antagonist. The... Agent: Duane Morris LLP Patent Department

20080020029 - Drug delivery system using an immune response system: The object of the present invention is to provide a drug delivery composition which allows efficient accumulation of an administered substance such as an anti-cancer drug and the like in a target site. The present invention provides a drug delivery liposome composition for delivering a substance to be administered to... Agent: Greenblum & Bernstein, P.L.C

20080020031 - Methods and compositions for altering mucus secretion: Methods and compounds for increasing or decreasing mucus secretion in subjects, and particularly mucus secretion in the airways, are described. Methods of screening compounds for the ability to increase or decrease mucus secretion are also described.... Agent: Myers Bigel Sibley & Sajovec

20080020030 - Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms: The use of 7-ter-butoxyiminomethylcamptothecin is described in the preparation of a medicament useful for the treatment of uterine neoplasms, particularly cancer of the endometrium and of the neck of the womb.... Agent: Nixon & Vanderhye, PC

20080020032 - Hydrophobic abuse deterrent delivery system for hydromorphone: Disclosed herein are oral dosage forms of hydromorphone that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20080020033 - Oil or fat compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same: An oil or fat composition according to the present invention contains a LCPUFA supply compound as a first component, and phospholipids as a second component, the LCPUFA supply compound containing LCPUFA in its structure and being hydrolyzable to remove its LCPUFA, wherein respective proportions of the first component and the... Agent: Drinker Biddle & Reath (dc)

20080020034 - Butylphtualide soft gel capsule and its preperation procedure: The present invention discloses a novel dosage form of butylphthalide soft capsule and its preparation procedure. Butylphthalide soft capsule is composed of a coating material and a drug-containing oil. The drug-containing oil is basically composed of butylphthalide and diluent—vegetable oil, wherein the weight ratio of butylphthalide to oil ranges from... Agent: Knobbe Martens Olson & Bear LLP

20080020035 - Micronutrient formulations and related methods of manufacture: A micronutrient formulation system is provided and the system comprises: a first composition comprising alpha tocopherol and derivative esters of alpha tocopherol, the derivative esters of alpha tocopherol being selected from a group consisting essentially of alpha tocopheryl acetate, alpha tocopheryl palmitate, alpha tocopheryl succinate, alpha tocopheryl nicotinate and mixtures... Agent: Dan M. Dela Rosa, Esq.

20080020036 - Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers: There is provided a composition comprising at least one mucoadhesive polymer that is capable of forming a hydrogel and at one least water soluble polymer, and one or more enzymes, microorganisms, or antibodies. The formulation forms a hydrogel in aqueous solution that has mucoadhesive properties and that is capable of... Agent: Foley And Lardner LLP Suite 500

20080020037 - Acoustic pharma-informatics system: Compositions, systems and methods that allow for the detection of the actual physical delivery of a pharmaceutical agent to a body are provided. Embodiments of the compositions include an acoustic identifier and an active agent. The invention finds use in a variety of different applications, including but not limited to,... Agent: Bozicevic, Field & Francis LLP (proteus Biomedical, Inc)

20080020038 - Amorphous aripiprazole and process for the preparation thereof: Morphologically stabilized amorphous aripiprazole and process for preparing the same.... Agent: Swanson & Bratschun, L.L.C.

20080020039 - Controlled release formulations and associated methods: A pharmaceutical formulation having a geometric configuration that affects the release characteristics of active agents contained therein and associated methods are provided. In one aspect, a sustained release oral dosage pharmaceutical tablet may include a first layer having a first active agent, where the first layer is disposed between two... Agent: Thorpe North & Western

20080020040 - Unit dose form for administration of ibuprofen: An oral dosage form for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in separate compartments, in amounts suitable for three times per day administration.... Agent: Townsend And Townsend And Crew, LLP

20080020041 - Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid: Embodiments of a pharmaceutical formulation comprising an enteric material are disclosed. The embodiments release at least a portion of an active ingredient upon contacting gastric fluid. The remaining portion of the formulation releases active ingredient upon contacting intestinal fluid. Certain embodiments of the pharmaceutical composition comprise at least one active... Agent: Klarquist Sparkman, LLP

20080020042 - Dosage form of sodium ibuprofen: A non effervescent tablet of ibuprofen, comprising a tablet core and, if desired, a sugar or film coat, wherein the tablet core, based on the weight of the tablet core, consists of 50 to 100% by weight sodium ibuprofen hydrate and 50 to 0% by weight auxiliary material component and... Agent: Gibbons P.C.

20080020044 - Aqueous gel formulation and method for inducing topical anesthesia: Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count.... Agent: Leydig Voit & Mayer, Ltd

20080020043 - Dendrimer-drug conjugates: The present invention provides a drug-dendrimer conjugate comprising a central core, two or more linear hydrophilic molecules bonded thereto, a secondary core molecule bonded to at least a majority, if not all, of said first linear hydrophilic molecules, a drug or other biologically-active molecule bonded to the remainder of said... Agent: Robert J. Baran (t2-7h) Allergan, Inc.

20080020045 - Combination degradable and non-degradable matrices for active agent delivery: The present invention relates to relates to combination degradable and non-degradable matrices and related methods. In an embodiment, the invention includes an active agent delivery matrix including a degradable polymer network, a non-degradable polymer network, the non-degradable polymer network interspersed within the degradable polymer network, and an active agent. In... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20080020047 - Method for distributing a pharmaceutically active compound in an excipient: A process for uniformly distributing a pharmaceutically active particulate material in a pharmaceutically inert particulate material includes steps of providing a first layer of a pharmaceutically inert particulate material, disposing a layer of a pharmaceutically active particulate material on the first layer of pharmaceutically inert particulate material, passing the layers... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080020046 - Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them: Granulates have particles of metformin and particles of a fibrate. Pharmaceutical compositions contain such granulates. Processes prepare the granulates and the pharmaceutical compositions.... Agent: Merchant & Gould PC

20080020050 - Medicinal delivery system, and related methods: A method is provided of making a medicinal delivery system which satiates a craving in an individual when the medicinal delivery system is administered orally to the individual. A coating composition is applied on a saliva-soluble powder to establish a coated powder, the coating composition featuring an at least partially... Agent: Berenato, White & Stavish, LLC

20080020049 - Super-sparger microcarrier beads and precision extrusion deposited poly-epsilon-caprolactone structures for biological applications: In on aspect, the invention includes a microcarrier bead having a porous three-dimensional core having (a) a polymeric porous three-dimensional body having porosity of about 15 to about 90% such that at least 99% of pores are interconnected and have diameters of at most 200 microns, (b) an outer protective... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080020048 - Treatment of respiratory disease: Glycopyrrate or an analogue thereof is useful for the treatment of bronchospasm or as a rescue medication.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080020054 - Cosmetic and dermatological preparations containing transparent surface-coated titanium dioxide particles: The present invention relates to cosmetic and dermatological preparations for protecting human skin and hair against UV radiation, comprising surface-coated titanium dioxide particles which are transparent in the visible region and have a crystallite size of from 10 to 20 nm and a specific surface area of from 90 to... Agent: Connolly Bove Lodge & Hutz LLP

20080020051 - Method for producing cs particles and microcapsules using porous templates, cs particles and microcapsules, and the use thereof: A process for the production of CS particles (10) and microcapsules (12) is described, in which at least one active compound (4) is adsorbed in porous templates (2) (A), as a result of which templates (5) filled with active compounds are present. Subsequently, the templates (2) are provided (B) with... Agent: Patterson & Sheridan, L.L.P.

20080020053 - Solid dosage form comprising proton pump inhibitor and suspension made thereof: A solid rapidly gelling oral pharmaceutical dosage form, as well as aqueous suspensions prepared thereof, comprising an acid sensitive proton pump inhibitor as active ingredient distributed in a multitude of enteric coated pellets and a suspension modifying granulate comprising a rapidly dissolving diluent granulated together with a gelling agent chosen... Agent: White & Case LLP Patent Department

20080020052 - Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation: Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation. The preparation of it consists of the following steps: preparing the solution of paclitaxel, sodium alginate and dilvalent metal cations such as BaCl2 or CaCl2 etc. by order; mixing the paclitaxel solution and sodium alginate solution, and then mixing them with... Agent: Lau & Associates, LLC Michael N. Lau

20080020055 - Phenylephrine pharmaceutical formulations and compositions for colonic absorption: The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080020056 - Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease: A unique composition of a 5-amino salicylic acid (5ASA) and a phospholipid is disclosed for treating Inflammatory Bowel Disease (IBD), where the composition can be a mixture, a molecular association complex or a covalent compound of 5ASA and a reactive phospholipid covalently bonded together via a diazo linkage and to... Agent: T. Ling Chwang

20080020057 - Personal care composition containing microemulsified wax particles: Personal care compositions comprise (a) from about 5 wt. % to about 50 wt. % of a detersive surfactant, (b) from about 0.05 wt. % to about 20 wt. % of wax particles having a melting point of at least about 100° C. and an average mean particle size as... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080020058 - Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules: The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080020059 - Compositions and methods for topical treatment of skin infection: The present invention describes an extremely effective, simple, novel, inexpensive, safe and quick method to treat both acne and warts, each with a different etiology and different clinical symptoms, by topically applying an effective amount of one or more polyvalent metal compounds. The polyvalent metal compounds include, but are not... Agent: Merchant & Gould PC

20080020060 - Process for treating rhinitis: A colloidal suspension comprising elemental silver and/or one or more alloys of silver is mixed with either an over-the-counter rhinitis medicine or a prescription rhinitis medicine. The resulting mixture is administered to rhinitis patients in the form of a spray.... Agent: Michael A. O'neil Michael A. O'neil, P.C.

20080020061 - Therapeutic cream: Chemical compositions in cream form for the treatment of Bovine Mastitis in cows, which compositions are combinations of Aloe Vera, Colloidal Silver, Castor Oil, Glycosperse, Peppermint Oil, Peppermint Leaf, Tea Tree Oil, Oregano Oil, Poke Root, Vitamin C, Menthol crystals, Salt, Polysorbate 80 and Guar/Xanthan Gum, which provides a cream... Agent: Zachary T. Wobensmith, Iii

20080020062 - Nutritional composition for the treatment of pressure ulcers: The invention pertains to a method of treating or preventing pressure ulcers, comprising enterally administering to a subject in need thereof a composition comprising proteins, carbohydrates, fats, arginine or equivalents thereof, ascorbic acid equivalents and a-tocopherol equivalents, wherein arginine or equivalents thereof is administered in a daily amount of 3-15... Agent: Young & Thompson

20080020063 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080020064 - Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear: The instant invention provides preparations comprising an oxidizing antimicrobial agent such as chlorine dioxide and a heterocyclic compound that improves the antibacterial effect of the oxidizing antimicrobial agent preparation. The invention has particular use as an eye care preparation such as an eye drop. The invention further provides methods for... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20080020065 - Rapid-melt compositions, methods of making same and method of using same: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.... Agent: Thorpe North & Western, LLP.

20080020066 - Method of relieving pain using sulfur bars: Pain can be relieved by passing a bar of elemental sulfur over a painful area. The bar can be of any size or dimension and can be rolled or rubbed across the painful area. The bar can be comprised completely of elemental sulfur, be coated with elemental sulfur, or have... Agent: Gilbert Johnson

20080020067 - Skin moisturizer: The present invention provides an oral skin moisturizer that is readily available to those who are suffering from dry skin, has no side effects, and when orally ingested, enhances the moisture-retaining ability of the skin. The invention also provides food products or the like that contain the oral skin moisturizer.... Agent: Drinker Biddle & Reath (dc)

20080020068 - Use of trisubstituted benzopyranones: The present invention relates to the use of trisubstituted benzopyranones for the treatment or propylaxis of pathological conditions associated with oxidative stress and/or inflammatory reactions as well as to novel trisubstituted benzopyranones and the physiologically acceptable salts thereof. The present invention further relates to plant extracts, medicaments, dietetic food products... Agent: Edwards Angell Palmer & Dodge LLP

20080020069 - Beverage precursor and process for the manufacture thereof: The present invention provides a beverage precursor comprising tea material and food-grade additive, wherein the beverage precursor is present in an amount wherein contact of the beverage precursor with 250 ml water for 2 minutes at 90° C. produces a beverage comprising catechins in an amount of between 0.05% and... Agent: Unilever Intellectual Property Group

20080020070 - Citrus fruit skin extract for angiogenesis promotion: The use of a citrus fruit skin extract for promoting angiogenesis, or treating a disease or disorder where it is desirable to promote angiogenesis. Such diseases include coronary heart disease, stroke, or ulcers. A composition comprising an extract of citrus fruit skin suitable for use in promoting angiogenesis, or treating... Agent: Knobbe Martens Olson & Bear LLP

20080020071 - Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers: A composition protects against, minimizes the effects of, and hastens recovery from the typical symptoms associated with an alcohol induced hangover. The composition includes superoxide dismutase (SOD), and prickly pear cactus (OFI). In addition, sesamin and alpha-lipoic acid work with the SOD and OFI for enhanced antioxidant and therapeutic effects.... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco P.l.

20080020072 - Green garlic and methods of production: A new vegetable, referred to herein as green garlic, grown from garlic bulbils is disclosed. In particular examples, the green garlic is rich in one or more thiosulfinates. Methods of producing green garlic are also disclosed. In some examples, such methods permit year-round commercial production of green garlic.... Agent: Klarquist Sparkman, LLP

20080020073 - Use of oligosaccharides to stimulate beta-endorphin production: The invention concerns the use of at least an oligosaccharide comprising 2 to 6 sugars and containing at least 2 galactose units, preferably 2 vicinal end-of-chain galactose motifs, or a plant extract containing same, as a cosmetic or dermatological agent, in particular for stimulating the beta-endorphin production in the skin.... Agent: Millen, White, Zelano & Branigan, P.C.

20080020074 - Use of a cosmetic compound for promoting skin depigmentation: The present invention relates to the use of an extract of Alchemilla vulgaris in a depigmenting cosmetic composition. The present invention also relates to a cosmetic treatment method for depigmenting the skin, by application to the skin of a cosmetic composition containing an extract of Alchemilla vulgaris.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080020075 - Topical cypress essential oil composition for stretch marks: A method for reducing or minimizing the appearance of striae distensae lesions by topically applying a composition comprising sweet almond oil, wheat germ oil, olive oil, castor oil, and cypress essential oil.... Agent: Bachman & Lapointe, P.C.

20080020076 - Methods and therapies for potentiating a therapeutic action of an alpha-2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha-2 adrenergic receptor agonists: Combination therapies of an alpha-2 adrenergic receptor agonist and an alpha-2 adrenergic receptor antagonist at a concentration effective to potentiate but not antagonize a therapeutic effect of the alpha-2 adrenergic receptor agonist are provided. Also provided are methods for use of these combination therapies in potentiating the therapeutic effects of... Agent: Licata & Tyrrell P.C.

20080020077 - Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts: The invention relates to a combination of plant extracts which can be used in a topical composition. The combination of plant extracts is based on gooseberries, black orchids and black tulips, the content thereof ranging from 5% to 90% in relation to the total weight of the combination. Application: treatment... Agent: Buchanan, Ingersoll & Rooney PC

20080020078 - Compositions and methods for controlling insects: Pest control compositions, blends, and formulations are disclosed. The blends contain, in a synergistic combinations, at least two ingredients such as Lilac Flower Oil, D-Limonene, Thyme Oil, Lime Oil, Black Seed Oil, Wintergreen Oil, Linalool, Tetrahydrolinalool, Vanillin, Isopropyl myristate, Piperonal (aldehyde), Geraniol, Geraniol 60, Triethyl Citrate, and Methyl Salicylate.... Agent: Sonnenschein Nath & Rosenthal LLP

20080014142 - Method of measuring and of selecting compositions of enhanced hydration value: The invention relates to method of measuring and selecting compositions having enhanced post wash hydration.... Agent: Unilever Intellectual Property Group

20080014141 - Substance binding human igg fc receptor iib (fcyriib): The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcγRIIb or FcγIIa.... Agent: Fulbright & Jaworski, LLP

20080014145 - Abalone settlement bioassay for anti-seizure substance screening: The present invention describes a method for utilizing marine mollusks in a novel assay for screening candidate substances for anti-epileptic/anti-seizure/anti-convulsant activity. The purpose of the invention is to facilitate the discovery of new treatments for neurological and mental diseases. In particular the use of a larval settlement assay using the... Agent: David Joseph Anschel

20080014152 - Intranasal delivery of clenbuterol across the cribriform plate and into the brain: The intranasal delivery of an effective amount of NGF inducers, such as clenbuterol, to the brain.... Agent: Philip S. Johnson Johnson & Johnson

20080014153 - Topical preparation for application to the skin containing natural oil of the evening primrose (oenothera biennis) (=oleum oenotherae) and osmolytes originating from extremophilic microorganisms: The invention relates to formulations comprising natural oils and fats that contain an osmolyte originating from extremophilic microorganisms and unsaturated fatty acids, with the osmolyte being present in an amount ranging between 0.01 and 50 wt. % based on the total weight of the formulation. The invention also relates to... Agent: Berliner & Associates

20080014166 - Cosmetic or pharmaceutical compositions comprising modified polyorganosiloxanes: The linear organopolysiloxane-polyoxyalkylene copolymers of the formula (I) can be used in an advantageous way in cosmetic or pharmaceutical compositions. Moreover, they are suitable particularly for the cleansing and care of the hair and the skin, as emulsifier in emulsions, preferably in O/W or W/O emulsions, and as conditioners.... Agent: Clariant Corporation Intellectual Property Department

20080014168 - Dispersed particle compositions for enhancing post wash hydration comprising amphiphiles and moisturization additives of defined hlb: The invention relates to compositions having enhanced post wash hydration by ensuring component or components of the composition meet selected defined criteria.... Agent: Unilever Intellectual Property Group

20080014163 - Protective applicator, composition, and method: A product for protecting a non-application keratinous surface from inadvertent application of cosmetic being applied to an application keratinous surface comprising a protective composition contained in a receptacle having an applicator for applying the protective composition to the area to be protected prior to application of the cosmetic and method... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080014170 - Drug delivery polyanhydride composition and method: The disclosure is generally directed to a biodegradable polymer composition comprising a drug-containing polymer component having a backbone containing one or more therapeutic drugs that are linked together by anhydride linkages, such that molecules of the drug are released upon biodegradation of the component. The biodegradable polymer composition also comprises... Agent: Perkins Coie LLP

20080014173 - Hepatitis c virus inhibitors: e

20080014177 - Devices, methods, and systems for accessing native neurons through artificial neural mediators (anms): The present invention relates to devices, methods, and systems for accessing native neurons in the nervous system of an animal. Specifically, one or more artificial neural mediators (ANMs) each comprising a neural cell are first formed, and neural connection is then established between the ANMs and one or more native... Agent: Scully Scott Murphy & Presser, PC

20080014176 - Method of inducing tolerance to betaap 1-42 and myelin basic protein: UVB irradiation of white blood cells in order to induce tolerance to antigenic βAP 1-42. To treat Alzheimer's Disease in a patient, irradiate autologous white blood cells with UVB light to cause tolerance therein. Combine the tolerized cells with βAP 1-42 to form a mixture. To treat stroke or multiple... Agent: Philip S. Johnson Johnson & Johnson

20080014188 - Manufacture of highly phosphorylated lysosomal enzymes and uses thereof: This invention provides compositions of highly phosphorylated lysosomal enzymes, their pharmaceutical compositions, methods of producing and purifying such compounds and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases.... Agent: Marshall, Gerstein & Borun LLP

20080014143 - Methods and compositions for targeting gc1qr/p32: Disclosed are compositions and methods useful for targeting gC1q/p32 receptors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells, and to areas of inflammation.... Agent: Needle & Rosenberg, P.C.

20080014144 - Methods of treatment with drug loaded polymeric materials: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, hone repair or regeneration materials, and other applications where the microparticles... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080014146 - System and method for determining individualized medical intervention for a disease state: A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular... Agent: Snell & Wilmer L.L.P. (main)

20080014150 - Compositions and method for treating precancerous virus infection and prevention of cancer: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.... Agent: Alfred M. Walker

20080014149 - Methods and compositions for imaging and biomedical applications: The present invention is directed to detectable compositions and methods for making and using such compositions. Detectable compositions comprise detectable constructs comprising a detectable agent. Due to the actions of a specific bioactivity in vivo or in vitro, the detectable construct is altered in some manner so that the detectable... Agent: Troutman Sanders LLP

20080014148 - Perturbed membrane-binding compounds and methods of using the same: The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.... Agent: Pearl Cohen Zedek Latzer, LLP

20080014147 - Tumor specific fluorescent dye: e

20080014151 - Device and method for hand washing: A device and method for washing a person's hands includes first and second cleaning agents having an indicator that is visually responsive to interaction of the cleaning agents. The cleaning agents may have different pH characteristics and the indicator is responsive to changes in these pH characteristics as the cleaning... Agent: Harshaw Research, Inc.

20080014155 - Clear sunscreen compositioin: The present invention relates clear sunscreen compositions. The compositions include an organic sunscreen and an alcohol. In certain embodiments, the compositions include a rheology modifier such as a non-ionic polymer and an anti-pilling agent such as a cationic polymer.... Agent: Philip S. Johnson Johnson & Johnson

20080014158 - Novel block polymers and cosmetic compositions and processes comprising them: The present invention relates to novel block polymers comprising at least one first block and at least one second block that are incompatible with each other, have different glass transition temperatures (Tg), and are linked together via an intermediate segment comprising at least one constituent monomer of the at least... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080014154 - Novel ethylene copolymers, compositions containing said copolymers and treatment method: The invention relates to novel ethylene copolymers comprising 10-60% polyethylenglycol(meth)acrylate monomers and 40-90% substantially cationic monomer. Compositions, in particular cosmetic or pharmaceutical compositions, containing the inventive copolymers and a cosmetic treatment method using said copolymers are also disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080014156 - Photoprotectant composition for preventing sunburn and sun damage to the skin: Photoprotectant compositions and methods of using the compositions to protect skin from sunburn and sun damage are disclosed.... Agent: Edwards Angell Palmer & Dodge LLP

20080014157 - Skin or hair treatment agents with protective effect: The invention relates to agents for the protective, conditioning, detersive or cosmetic treatment of skin or hair that contain pyridinols or pyrimidinols or their mixtures.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080014159 - Therapy for melanin related afflictions: Methods for treating melanin related afflictions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a melanin related affliction.... Agent: Allergan, Inc.

20080014160 - Antiperspirant gel compositions: The present invention relates to antiperspirant compositions comprising a cationic hydrophobically modified polymeric gelling agent and an acidic antiperspirant compound. The antiperspirant compositions are transparent, phase stable, non-whitening and non-staining to the skin and clothing following topical application. The present invention also is directed to methods of using the antiperspirant... Agent: Legal Department Lubrizol Advanced Materials, Inc

20080014161 - Cosmetic compositions comprising polymers comprising complementary chemical functional groups: The invention relates to cosmetic compositions comprising at least two polymers comprising complementary chemical functional groups, capable of forming a coat on a keratin material, such as hair, a cosmetic process comprising the use of these polymers on the keratin material, such as the hair, and also their use for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080014162 - Method to treat skin in need of a calmative using at least one c-glycoside derivative: The present invention concerns a non-therapeutic method to prevent and/or treat a skin in need of a calmative using a C-glycoside derivative.... Agent: Oliff & Berridge, PLC

20080014167 - Surfactant-containing cleansing composition with special proteins: A surfactant-containing cleansing composition is comprised of a surfactant and (a) at least one protein from yogurt and (b) one or more substances from the group of plant extracts and/or plant milks and/or vitamins, provitamins and vitamin precursors, and derivatives of vitamins, provitamins and vitamin precursors in the weight ratio... Agent: Paul & Paul

20080014164 - Mascara containing wax and filler: Composition useful for coating keratinous fibres containing an aqueous phase, at least one filler, at least one film-forming polymer in the form of solid particles dispersed in the aqueous phase and at least one wax such that the total content of wax(es) represents at least 21% by weight with respect... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080014165 - Hair and scalp composition with a crosslinked silicone elastomer and method of using same: The present invention provides a water-based composition comprising a non-emulsifying crosslinked silicone elastomer in an amount effective to decrease the amount of sebum on the hair or scalp. The water-based compositions of the present invention are in non-emulsion form. More preferably, the water-based compositions of the present invention have a... Agent: Joan M. Mcgillycuddy, Esq. Avon Producs Inc.

20080014169 - Compositions for topical enzymatic debridement: Formulations are described for the treatment by enzymatic debridement of wounds and ulcers. The formulations have a clear, transparent composition that allows for easy visualization of the wound, and are non-staining for easy clean up. These formulations can also exhibit increased enzymatic debridement activity, improved post-treatment lubricity and coating occlusivity,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080014171 - Device for dispensing bark beetle pheromone in a controlled manner: The present invention relates to a device in the form of a container made of a polymer material, which container has one or more sealed chambers, each of which comprise a liquid pheromone comprising 2-ethyl-1,6-dioxaspiro[4,4]nonane, methyl 2,4-decadiene-carboxylate and at least one alcohol selected among 2-methylbut-3-en-2-ol and 2-methylbut-3-yn-2-ol, where at least... Agent: Hutchison Law Group PLLC

20080014174 - Method for treating tumors, infectious diseases, and autoimmune diseases with an activated hla matching donor-originating lymphocyte: According to the present invention, HLA matching donor-originating activated lymphocytes highly effective in the treatment of patients with tumors, viral infections and autoimmune diseases are prepared by collecting cells contained in peripheral blood originating from an HLA matching donor or peripheral blood originating from an HLA matching donor achieving micro-chimerism... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080014172 - Use of il-17 in the treatment of fertility-related disorders: The present invention is directed to methods for ameliorating reproductive disorders. More specifically, the present invention describes methods and compositions for using IL-17 in the treatment of various infertility-related defects.... Agent: Marshall, Gerstein & Borun LLP

20080014175 - Methods and compositions for viral enhancement of cell killing: The present invention is directed to novel methods of enhancing the effectiveness of DNA damaging agents by exposing cells to viruses prior to or during exposure to the damaging agent. In certain embodiments of the invention, the DNA damaging agent is ionizing radiation, the virus is an adenovirus, and the... Agent: Marshall, Gerstein & Borun LLP

20080014183 - Anticancer agent containing dendritic cell having rna virus transferred thereinto: The present invention provides anticancer agents comprising dendritic cells introduced with RNA viruses. The present invention also provides methods for producing anticancer agents, which comprise the step of preparing dendritic cells introduced with RNA viruses. The present invention also provides methods for treating cancers using dendritic cells introduced with RNA... Agent: Clark & Elbing LLP

20080014185 - Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom... Agent: Davis Wright Tremaine LLP/los Angeles

20080014184 - Methods of treating fibromyalgia caused by small intestinal bacterial overgrowth: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom... Agent: Davis Wright Tremaine LLP/los Angeles

20080014181 - Cell separation apparatus and methods of use: The present invention provides automated devices for use in supporting various cell therapies and tissue engineering methods. The present invention provides an automated cell separation apparatus capable of separating cells from a tissue sample for use in cell therapies and/or tissue engineering. The cell separation apparatus can be used in... Agent: Thelen Reid Brown Raysman & Steiner LLP

20080014180 - Hemangio-colony forming cells: Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080014178 - Method for stimulating mammalian cells and mammalian cell: The current invention relates to methods for stimulating mammalian cells to enhance their ability to cross the blood-brain-barrier and to phagocytose and degrade beta-amyloid plaques in the brain. The current invention also relates to cells obtained by the method of the invention. The current invention also relates to methods for... Agent: Nixon & Vanderhye, PC

20080014182 - Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same: A population of expanded adult islet beta cells is provided as well as a population of expanded and redifferentiated adult islet beta cells. Methods of generation of the populations of cells are provided.... Agent: Martin D. Moynihan Prtsi

20080014179 - Tissue transplantation compositions and methods: A biomedical material for transplant to a subject is provided according to embodiments of the present invention which includes an isolated donor tissue enzyme-treated to reduce the amount of proteoglycans in the donor tissue compared to untreated tissue. Isolated cells are optionally added to the enzyme-treated donor tissue, including leukocytes,... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080014186 - Hla-a24 or hla-a2 binding peptides of parathyroid hormone-related protein: A cancer antigen peptide which is a partial peptide derived from parathyroid hormone-related protein, and which is capable of binding to an HLA-A24 or HLA-A2 antigen and being recognized by cytotoxic T lymphocytes, or a derivative thereof having the functionally equivalent properties, can be useful for the treatment and prevention... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080014187 - Compositions and methods for treating hypertension and inflammation: The present invention relates to pharmaceutical compositions for reducing essential hypertension and systemic inflammation. While many drugs have been found to treat hypertension, the currently available drugs often do not maintain reduced blood pressure at the preferred norm of 115/75 mm Hg or less throughout a 24 hour period. The... Agent: Bryant R. Villeponteau

20080014189 - Diaminotriazoles useful as inhibitors of protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080014190 - Proteinases destroy cancer tumor's solid structure and kill cancer cells locally: A proteinase therapy has been invented to eliminate solid-tumors by destroying tumors' solid structure and killing cancer cells by cleaving vital extracellular matrix proteins C-terminally, N-terminally or both with cell membrane intact and limited adverse effects. The micro-scale intratumoral Tumorase therapy is tumor specific but not cancer type specific. Tumorase... Agent: Yong Qian, Ph.d. Biomedicure LLC

20080014192 - Methods for the diagnosis and treatment of fungal infections caused by microorganisms producing glucosylceramide: Methods for the diagnosis and treatment of fungal infections caused by microorganisms producing glucosylceramide are provided. In particular, methods for diagnosing or predicting dissemination of a fungal infection from the lungs to the blood stream of a patient are provided. Methods for treating a fungal infection and/or preventing the dissemination... Agent: Fulbright & Jaworski L.L.P.

20080014193 - Modulation of excitable tissue function by peripherally administered erythropoietin: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral... Agent: Jones Day

20080014191 - Treatment of protein misfolding: The present invention is directed to preventing the consequences of the misfolding of proteins, such as those associated with protein folding diseases. Provided are methods of treatment that involve administering an agent that decreases the level of the heat shock protein ATPase Aha1 and/or related molecules with similar function. Such... Agent: Biotactica, LLC

20080014195 - Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases: A method of treatment or prophylaxis of stroke and other neurological diseases in a human which comprises administering an effective amount of a MAG antagonist or anti-MAG antibody including altered antibodies and functional fragments thereof.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080014196 - Compositions and methods for modulating vascular development: The present invention provides methods of using a DLL4 modulator to modulate vascular development. Furthermore, methods of treatment using DLL4 modulators, such as DLL4 antagonists, are provided.... Agent: Genentech, Inc.

20080014194 - Prevention and treatment of synucleinopathic and amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic... Agent: Townsend And Townsend And Crew, LLP

20080014197 - Neutralizing human anti-igfr antibody: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080014199 - Assessing cancer and vimentin: This document provide methods and materials related to determining whether or not a mammal (e.g., a human) having cancer (e.g., leukemia) is susceptible to a poor outcome. For example, this document provides methods and materials involved in using the level of vimentin expression in leukemia cells from a mammal to... Agent: Fish & Richardson P.C.

20080014198 - Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels: Agents that perturb the EGF signaling pathway and that are known to be useful in the treatment of cancer are found also to result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. This... Agent: Marina Larson & Associates, LLC

20080014200 - Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents: e

20080014201 - Cxcl13 antagonists and their use for the treatment of inflammatory diseases: Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFα antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic... Agent: Philip S. Johnson Johnson & Johnson

20080014202 - Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria: The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The... Agent: Lahive & Cockfield, LLP

20080014203 - Antibodies against insulin-like growth factor i receptor and uses thereof: An antibody binding to IGF-IR, being of human IgG1 or IgG3 type and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 98%, and in addition the amount of NGNA is 1% or less... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080014204 - Compositions against sars-coronavirus and uses thereof: The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.... Agent: Trask Britt

20080014205 - Neutralizing antibodies to influenza viruses: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7... Agent: Heller Ehrman LLP

20080014206 - Targeting of triacylglycerol synthase gene for tuberculosis treatment: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.... Agent: Beusse Wolter Sanks Mora & Maire

20080014207 - Iap bir domain binding compounds: s

20080014208 - Fusion proteins, uses thereof and processes for producing same: This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human β-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain... Agent: Cooper & Dunham, LLP

20080014211 - Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic and therapeutic purposes: Embodiments of the present invention relate to methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response. The methods and compositions disclosed herein, can be used for prophylactic or therapeutic purposes. Further embodiments provide... Agent: Sonnenschein Nath & Rosenthal LLP

20080014209 - Peptide mimics of conserved gonococcal epitopes and methods and compositions using them: The present invention relates to peptide mimics of a conserved gonococcal epitope of Neisseria gonorrhoeae, which epitope is not found on human blood group antigens. This invention also relates to methods and compositions using such peptide mimics for the prophylaxis of gonorrheal infections.... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080014210 - Peptides and antibodies to muc 1 proteins: The invention relates to methods of inhibiting proliferation or growth of tumor cells and/or inducing cell death in cancer cells. This invention relates to the use of antibodies, hybridomas and pharmaceutical compositions containing same, for inhibiting growth or proliferation and inducing death in epithelial, colon, lung, breast and ovarian tumor... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080014212 - Cloned genomes of infectious hepatitis c viruses and uses thereof: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral... Agent: Knobbe, Martens, Olson & Bear, LLP

20080014214 - Composition and method for inducing protective vaccine response using sdf-1: A method for inducing a protective immune response is disclosed, the method utilizing a composition comprising a CXCR3-binding chemokine and stromal cell-derived factor 1 which may be administered in conjunction with a protein, peptide, polynucleotide, or other target antigen to promote the development of regulatory T cells and boost the... Agent: Donna J. Russell

20080014215 - Animal bioreactors: The present invention relates to the use of the digestive tract of an animal as a bioreactor for the production of a product of interest.... Agent: Howrey LLP

20080014216 - Prime -boost vaccine for the protection of equines against viral infection: It has been found that adequate protection against viral infection in equines can be achieved when vaccination with a live viral vaccine (prime) is followed by vaccination with an inactivated vaccine (boost) for the same virus, wherein the two shots are given no longer than 8 weeks apart. The invention... Agent: Intervet Inc. Patent Department

20080014217 - Influenza vaccine: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080014218 - Use of tight junction agonists to facilitate pulmonary delivery of therapeutic agents: The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pulmonary mucosa.... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20080014219 - Method of immunization against the 4 dengue serotypes: The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080014220 - Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52: An immunogenic composition and methods for producing said composition, the composition comprising VLPs from HPV 16 and 18 and at least one other HPV cancer type, the other cancer type being selected from the list consisting of HPV types 31, 45 and 52, wherein the dose of the VLP of... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080014221 - Mycoplasma hyopneumoniae vaccine: The invention provides a novel method of vaccination of a pig against Mycoplasma hyopneumoniae by administering to a weaned piglet or a sow, a single dose of an effective amount of a Mycoplasma hyopneumoniae vaccine. The Mycoplasma hyopneumoniae vaccine can be a whole or partial cell inactivated or modified live... Agent: Judy Jarecki-black, Ph.d., J.d.

20080014222 - Cancer immunotherapy compositions and methods of use: Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility... Agent: Dla Piper US LLP

20080014223 - Syrup composition comprising dexibupropen as an active ingredient and method for the preparation thereof: A dexibupropen syrup composition comprising dexibupropen ((S)-ibupropen) having an average particle size ranging from 10 to 300 μm as an active ingredient, which does not contain glycerine and has a viscosity ranging from 500 to 3,000 cps and pH ranging from 3.0 to 6.0, shows improved safety, uniformity of efficacy,... Agent: Sughrue Mion, PLLC

20080014225 - Method and system of manufacturing master-batch of ultra fine talc powders: A method of manufacturing ultra-fine talc powder materials includes the steps of (a) adding a predetermined amount of pre-treatment agent with a predetermined amount of talc powders to prevent the talc powders from agglomerating with each other; (b) performing activating treatment to the pre-treated talc powders to form activated talc... Agent: Raymond Y. Chan

20080014226 - Method of formulating and manufacturing non-pharmaceutical cosmetic and personal care products: As disclosed herein, a series of compounds that are not generally intended for internalization such as cosmetic and skin care products are formulated using chirally correct components, organic ingredients, and natural or naturally derived ingredients. In this fashion, any deleterious biological effects due to inadvertent or incidental internalization may be... Agent: Wright Law Group, PLLC Attn: Mark F. Wright

20080014224 - Methods of making compositions comprising films: The invention relates to methods of making films having active ingredients. A film that is substantially free of active ingredient is introduced into a medium comprising an active ingredient. At least a portion of the active ingredient is transferred from the medium to the film. The films can be used... Agent: Colgate-palmolive Company

20080014228 - Solid form: An enrobed solid form comprising a film enrobing a compacted fill material having at least one active material, the solid form shows a weight loss that is less than 1% during a 30 minutes USP Friability Test, the fill material having a density of at least 0.5 g/ml based on... Agent: Patent Administrator Fmc Corporation

20080014231 - Treatment articles capable of delivering intensive care and overall treatment simultaneously: The present invention relates to treatment articles capable of delivering intensive care and overall care simultaneously. The articles comprise a first substrate, a second substrate which substantially covers the first substrate at-use, a first treatment composition and a second treatment composition wherein the delivery of the skin care active to... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080014229 - Administration of compounds that increase glutathione levels in the melanocytes for the treatment of canities: At least one compound that increases the level of glutathione (GSH) in the melanocytes of hair follicles, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents that slow hair loss and/or promote... Agent: Buchanan, Ingersoll & Rooney PC

20080014230 - Cosmetic compositions combining a c-glycoside derivative and an n-acylamino amide derivative: The present invention relates to a cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium, at least one N-acylamino amide derivative and at least one C-glycoside derivative.... Agent: Oliff & Berridge, PLC

20080014227 - Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing thes: Novel heterocyclic derivatives based on N6-substituted adenine, having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the... Agent: Notaro And Michalos

20080014233 - Hybrid coated cosmetic powders and methods of making and using same: A hybrid coating material and process for pigments and other powders, for example cosmetic powders employs an organometallate, for example a titanate, and a functionalized silicon compound, for example a trialkoxysilane or a functionalized polysiloxane, which covalently bond to each other and to the substrate powder. The coated powders can... Agent: Brown, Rudnick, Berlack & Israels, LLP.

20080014234 - Novel block polymers and cosmetic compositions and processes comprising them: The present invention relates to novel block polymers comprising at least one first block and at least one second block that are incompatible with each other, have different glass transition temperatures (Tg), and are linked together via an intermediate segment comprising at least one constituent monomer of the at least... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080014235 - Novel block polymers and cosmetic compositions and processes comprising them: The present invention relates to novel block polymers comprising at least one first block and at least one second block that are incompatible with each other, have different glass transition temperatures (Tg), and are linked together via an intermediate segment comprising at least one constituent monomer of the at least... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080014232 - Two-coat make-up product, its use and a kit containing the make-up product: A cosmetic make-up product containing a first and a second composition, the first composition comprising, in a physiologically acceptable medium, dispersed polymer particles surface-stabilized with a stabilizer in a liquid organic phase and a coloring agent, and the second composition comprising a second physiologically acceptable medium.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080014236 - Poly(ester-amide) elastomers and their use with implantable medical devices: The present invention relates to implantable medical devices comprising poly(ester-amide) elastomers in coating layers on the device.... Agent: Squire, Sanders & Dempsey LLP

20080014239 - Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions: The present invention is related to heparin-like compounds characterized by their capacity of inhibiting collagen-induced platelet aggregation in flowing whole blood and their use for prophylactic treatment of arterial thrombosis associated with vascular or microvascular injury and interventions. Said properties are related to a high coupling density of negatively charged... Agent: Buchanan, Ingersoll & Rooney PC

20080014238 - Implantable medical devices comprising semi-crystalline poly(easter-amide): The current invention relates to an implantable medical device made of semi-crystalline poly(ester amide) (PEA) polymer.... Agent: Squire, Sanders & Dempsey LLP

20080014240 - Stereocomplex-forming composition and implantable medical device comprising same: The present invention relates to a composition of a first single enantiomer homopolymer and a separate stereocomplex formed of a second single enantiomer homopolymer and it mirror image enantiomer, wherein the first and second single enantiomer homopolymers can be the same or different.... Agent: Squire, Sanders & Dempsey LLP

20080014237 - Sustained release compositions, process for producing the same and use thereof: Sustained release compositions containing a physiologically active substance or its salt, hydroxynaphthoic acid or its salt and a lactic acid-glycolic polymer or its salt, wherein the product of the weight-average molecular weight of the lactic acid-glycolic acid polymer by the amount (μmol) of the terminal carboxyl group per unit mass... Agent: Foley And Lardner LLP Suite 500

20080014241 - Implantable medical device comprising a pro-healing poly(ester-amide): The present invention relates to implantable medical devices, in particular stents, comprising pro-healing poly(ester-amide)s.... Agent: Squire, Sanders & Dempsey LLP

20080014243 - Metallic implant and process for treating a metallic implant: A process for treating a metallic implant consisting essentially of treating the metallic implant with a solution of hydrofluoric acid, which solution has a pH between 1.6 and 3.0.... Agent: Fish & Richardson PC

20080014242 - Synthetic bone substitute material: The invention includes a synthetic bone substitute material suitable for use as a replacement for cancellous bone in a bone graft composition, the material comprising a reticulated framework of interconnecting bioceramic struts defining an interconnecting interstitial void volume, and a solid non-porous composition substantially filling the interstitial void volume and... Agent: Alston & Bird LLP

20080014245 - Drug-eluting implantable medical device with free radical scavenger for protecting drugs during sterilization and related method: The current invention relates to devices and methods for protecting drugs coated on implantable medical devices, in particular drug-eluting stents, involving the inclusion of free or, preferably at present, polymer-bound stable nitroxides in a coating layer on the device that is either the same layer that contains the drug or... Agent: Squire, Sanders & Dempsey LLP

20080014244 - Implantable medical devices and coatings therefor comprising physically crosslinked block copolymers: The current invention relates to physically crosslinked block copolymers, in particular triblock copolymers in which the end blocks are capable of physical crosslinking.... Agent: Squire, Sanders & Dempsey LLP

20080014246 - Methods and compounds for controlled release of recombinant parvovirus vectors: The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the... Agent: Myers Bigel Sibley & Sajovec

20080014247 - Metal-containing formulations and methods of use: Metal-containing materials, as well as their preparation, formulations, and use are disclosed.... Agent: Fish & Richardson PC

20080014248 - Photosensitizer containing indole-3-alkylcarboxylic acid, and kit for photodynamic therapy containing the same: The present invention relates to a photosensitizer containing indole-3-alkylcarboxyl acid (ICA), and kit for photodynamic therapy containing the same. More specifically, the present invention is directed to a pharmaceutical composition comprising ICA or a pharmaceutically acceptable salt thereof, and a novel method for photodynamic therapy using ICA as a photosensitizer.... Agent: The Nath Law Group

20080014249 - Compositions and therapeutic methods involving isoflavones and analogues thereof: Isoflavone compounds are described and recommended as therapeutic agents. Exemplified and preferred compounds are (a). Indications show compounds have good competitive binding to estrogen receptors. This is exemplified.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080014250 - Bifunctionalized polysaccharides: The present invention relates to a dextran and/or dextran derivative bifunctionalized by at least one imidazolyl radical Im and at least one hydrophobic group Hy, the said radical and the said group being each identical and/or different and grafted or bonded to the dextran and/or dextran derivative via one or... Agent: Oliff & Berridge, PLC

20080014251 - Hemostatic compound and its use: A novel hemostatic compound includes a hemostatic agent and a transdermal migration-enhancing agent, the agents combined in a defined ratio and in a form capable of topical application to an abrasion, puncture or incision site and capable at the site of inhibiting bleeding. In accordance with one embodiment of the... Agent: Ater Wynne LLP

20080014252 - Topical compositions with long lasting effect: Topical pharmaceutical formulations and compositions for transdermal delivery of a variety of active agents are described. The formulations and compositions are formulated to provide a long lasting effect of the agent being delivered. The formulations and compositions of the present invention contain a transdermal vehicle and an adrenergic drug. The... Agent: Blank Rome LLP

20080014253 - Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof: The present invention relates to a lipid-based drug delivery system for administration of a lysolipid derivative present in a prodrug from, said prodrug furthermore being a substrate for extracellular phospholipase A2 to the extent that an organic radical can be hydrolytically cleaved off, whereas the aliphatic group of the lysolipid... Agent: Nath & Associates

20080014255 - Liposome bonded with antibody and polyalkylene glycol: A liposome wherein a compound containing a polyalkylene glycol moiety is bonded through a thioether group and an antibody is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, wherein an amount of the bonded compound and an amount of bonded antibody is... Agent: Greenblum & Bernstein, P.L.C

20080014254 - Stable crystal modifications of dotap chloride: The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.... Agent: Millen, White, Zelano & Branigan, P.C.

20080014256 - Oral formulations comprising tigecycline: Disclosed herein are pharmaceutical compositions comprising tigecycline for oral administration. The composition can comprise tigecycline having at least one enteric coating.... Agent: Wyeth/finnegan Henderson, LLP

20080014257 - Oral dosage forms: This invention relates to an oral dosage form of a pharmaceutically active ingredient comprising: (a) an outer capsule and (b) non-uniform pellets, having a non-uniform shape and/or size, contained within the capsule, wherein the pellets comprise a compressed powder comprising a pharmaceutically active ingredient. In one embodiment the active ingredient... Agent: Foley And Lardner LLP Suite 500

20080014258 - Use of fosfluridine tidoxil (ft) for the treatment of intraepithelial proliferative diseases: The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5′-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic keratosis. The Fosfluridine Tidoxil can be systemically administered alone or in combination with topical treatment agents.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080014259 - Compositions of r(+) and s(-) pramipexole and methods of using the same: Compositions of predetermined amounts of R(+) pramipexole and S(−) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.... Agent: Pepper Hamilton LLP

20080014260 - Solid dispersing vaccine composition for oral delivery: The invention disclosed herein relate to an oral vaccine in which the vaccine composition and adjuvant(s) are carried on a solid fast-dispersing dosage form. The vaccines are targeted toward mucosal tissue and the adjuvant serves to ensure sufficient residence time for the vaccine composition on the mucosal tissue to facilitate... Agent: Fitzpatrick Cella (catalent)

20080014261 - Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction: The present invention relates to compositions that comprise immediate release and extended release guaifenesin, extended release phenylephrine and immediate and extended release dextromethorphan. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Attn: Ellen Klann

20080014263 - Amorphous eprosartan mesylate and process for the preparation thereof: Eprosartan mesylate substantially in an amorphous form is disclosed. A composition comprising eprosartan mesylate in a solid form, wherein at least about 80% by weight of the solid eprosartan mesylate is in an amorphous form is also disclosed. The present invention also provides a process for preparing eprosartan mesylate substantially... Agent: M. Carmen & Associates, PLLC

20080014262 - Rapidly disintegrating tablet containing polyvinyl alcohol: The present invention provides a quickly disintegrating tablet which has quick disintegrability and solubility in an oral cavity, and does not have uncomfortable tastes such as bitterness, has a small variation of a tablet physical property even in storage under a humidifying condition, and has substantially no change in a... Agent: Birch Stewart Kolasch & Birch

20080014264 - Novel pharmaceutical compositions comprising levetiracetam: The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080014265 - Pharmaceutical composition as solid dosage form and method for manufacturing thereof: The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a... Agent: Foley And Lardner LLP Suite 500

20080014266 - Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent: A pharmaceutical composition, which composition comprises: an insulin sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent, and the use of such composition in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080014267 - Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction: The present invention relates to compositions that comprise an expectorant, an extended release antitussive, and an extended release decongestant, in liquid. Specifically, the compositions may comprise guaifenesin, and the tannate salts of phenylephrine and dextromethorphan. The present invention also includes methods for using these compositions for treatment of patients suffering... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Attn: Ellen Klann

20080014268 - Orally disintegrating layered compositions: The present invention is directed to multi-layered compositions for oral administration having at least one orally disintegrating layer and capable of maintaining layer cohesion. The present invention is also directed to methods of manufacturing such compositions.... Agent: Hunton & Williams LLP Intellectual Property Department

20080014269 - Oxacarbazepine film-coated tablets: The invention relates to formulations, e.g. film-coated tablets containing oxcarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 um... Agent: Novartis Corporate Intellectual Property

20080014270 - Methods for improved lipid metabolism and basal metabolic rate with lactoferrin: A pharmaceutical composition is provided having at least one kind to be selected from the group consisting of a lactoferrin group protein having lactoferrin and conalbumin, and an enzymatically decomposed product of the lactoferrin group protein having peptides corresponding to lactoferricin and lactoferricin of conalbumin as an active ingredient. The... Agent: Birch Stewart Kolasch & Birch

20080014271 - Novel pharmaceutical compositions comprising levetiracetam: The present invention relates to pharmaceutical compositions comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080014273 - Equine whole food supplements: Whole food equine formulations provided by the invention include well balanced nutritional supplements providing nutrients and vitamins, among other benefits. The whole food formulations generally promote, for example, better cell utilization instead of cell saturation, which results in increased overall general physiological and psychological health of subject animals including horses.... Agent: Mcguirewoods, LLP

20080014272 - Compositions and methods for treatment of chronic pain conditions: The present invention relates to methods, pharmaceutical compositions and kits for treating osteoarthritis associated pain, inflammation and improving function in a patient comprising a first therapeutic agent which comprises bicifadine or a pharmaceutically acceptable salt, enantiomer, solvate, hydrate, polymorph or prodrug thereof and a second therapeutic agent which comprises a... Agent: Jeffrey J. King, Esq. Black Lowe & Graham PLLC

20080014274 - Enhanced stability phenylephrine liquid compositions: An oral, liquid pharmaceutical composition is provided. The composition comprises phenylephrine and substantially aldehyde-free polyethylene glycol. The composition has phenylephrine stability compatible with the stability required for commercial preparations. Optionally, the composition may comprise one or more additional active agents.... Agent: Wyeth Patent Law Group

20080014276 - Methods and devices for forming treatment agent carriers: A method is described including passing a solution having a biodegradable polymer, a solvent and a treatment agent through an electrocharged nozzle to form particles encapsulating the treatment agent. The particles emitted from the electrocharged nozzle may be exposed to a charge opposite that of the nozzle. The particles may... Agent: Blakely Sokoloff Taylor & Zafman

20080014275 - Pharmaceutical suspensions and related methods: A pharmaceutical suspension having a therapeutically effective amount of phenylephrine and a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an... Agent: Philip S. Johnson Johnson & Johnson

20080014277 - Reduced-odor thiol compositions: The present invention provides compositions for and methods of delivering a therapeutically-effective dose of a malodorous, sulfide or disulfide group-containing compound, for example glutathione (reduced) and/or glutathione disulfide, in a vehicle that is effective to reduce the unpleasant odor and/or taste of the compound. The invention further provides methods for... Agent: Bingham Mccutchen LLP

20080014280 - Amorphous pregabalin and process for the preparation thereof: Pregabalin substantially in an amorphous form is disclosed. A composition comprising amorphous pregabalin in a solid form, wherein at least about 80% by weight of the solid is amorphous pregabalin in an amorphous form is also disclosed. The present invention also provides a process for preparing amorphous pregabalin substantially in... Agent: M. Carmen & Associates, PLLC

20080014278 - Metal-containing formulations and methods of use: Metal-containing materials, as well as their preparation, formulations, and use are disclosed.... Agent: Fish & Richardson PC

20080014279 - Methods for preparing compositions for repairing bone: This invention relates to an improved method of preparing an implantable gel or paste for placement between injured bones or placement in bony voids to induce regeneration, and the compositions produced thereby. Specifically, mineral, ceramic, or processed bone particles are coated with a high molecular weight polymer capable of forming... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080014281 - Chitin micro-particles as an adjuvant: A composition and method for the preparation of micro-particles of chitin (a naturally occurring polymer of N-acetyl-D-glucosamine), the characterization of chitin micro-particles as an immune adjuvant and the use of chitin micro-particles to enhance protective immunity against intracellular infectious agents and diseases as well as to inhibit allergic responses and... Agent: Akerman Senterfitt

20080014282 - Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations: The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and... Agent: Hoffmann & Baron, LLP

20080014283 - Treatment methodologies for preventing reflux induced adenocarcinoma of the esophagus: Medications for the prevention and treatment of the progression of gastroesophageal reflux disease to adenocarcinoma, and more specifically to medications that operate in accordance with a new mechanistic understanding of the sequence of changes whereby gastroesophageal reflux disease progresses to adenocarcinoma are provided. The medications for the prevention and treatment... Agent: Kauth , Pomeroy , Peck & Bailey ,llp

20080014284 - Disinfection of instruments: The invention relates to a powdered disinfectant containing a peroxide, an acylating agent and nonionic surfactants and to the use of this disinfectant for disinfecting surfaces and instruments, particularly in the medical field.... Agent: Ecolab Inc.

20080014285 - Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound: A method of treating brain injury involving intrathecally administering a composite powder comprising superparamagentic nanoparticle and a therapeutic agent compound, and then magnetically transporting the composite into an injured brain.... Agent: Philip S. Johnson Johnson & Johnson

20080014286 - Metal-containing materials: Metal-containing materials, as well as their preparation and use are disclosed. The metal-containing material can be, for example, an antimicrobial material, an anti-biofilm material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, anti-proliferative, MMP modulating material, an atomically disordered, crystalline... Agent: Fish & Richardson PC

20080014287 - Micronutrient combination product for use as a dietetic food supplement in age-related macular degeneration: Micronutrient combination product, wherein the micronutrient combination product comprises zeaxanthin, lutein, zinc and copper.... Agent: Bausch & Lomb Incorporated

20080014288 - Zinc-containing treatments for hyperphosphatemia: A method of treating hyperphosphatemia in a subject comprises the step of administering to the subject an effective amount of a pharmaceutically acceptable zinc salt. A pharmaceutical composition comprises a pharmaceutically acceptable carrier; a pharmaceutically acceptable zinc salt; and a phosphate sequestrant. In one embodiment, the phosphate sequestrant is selected... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080014289 - Vehicle and method for treating and preventing acne vulgaris and exfoliating the skin hypohalous acids: Vehicle and method is disclosed for treating and/or preventing skin disorders such as acne vulgaris and which exfoliates healthy skin by a topical application. The vehicle is a formulation incorporating hypohalous acid in a suitable pharmaceutical compound. The topical application comprises administering and scrubbing a therapeutically effective amount of hypohalous... Agent: Gerald Anderson

20080014290 - Composition and method of treating a sore throat: A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to... Agent: Connolly Bove Lodge & Hutz LLP Suite 800

20080014291 - Process for the production of multi-component mineral substance preparations: Not easily dissolvable a priori trace elements are therefore preferably in colloidal form, which is why biologic absorption is especially high. The effect of these mineral substance preparations on health and fitness are by far superior than the currently available mineral substance preparations, since they also all contain trace elements... Agent: Demont & Breyer, LLC

20080014292 - Composition for treating and/or preventing periodontal disease: A method for treating periodontal disease, which comprises administering an effective amount of a composition to one in need of treatment of periodontal disease, the composition comprising a Sasa extract and an organic acid.... Agent: Sughrue Mion, PLLC

20080014293 - Novel compound isolated from ginkgo biloba bark, isolation method thereof and antiplatelet composition containing the same: Disclosed herein are a novel compound isolated from Ginkgo biloba and a method for isolating the novel compound from Ginkgo biloba. The method comprises: (1) extracting Ginkgo biloba with alcohol to obtain a crude extract; (2) subjecting the Ginkgo biloba crude extract to solvent fractionation using an organic solvent; (3)... Agent: Park Law Firm

20080014294 - Compositions and methods for management of diabetes: A buckwheat extract comprising at least myo-inositol, D-chiro-inositol, a fagopyritol, one MAPK-stimulating compound, and one glucose-uptake inhibiting compound. A substantially pure glucose-uptake inhibiting compound selected from a buckwheat extract. A method for providing a glucose-uptake inhibiting extract from buckwheat seed comprising first contacting said buckwheat seed with a non-polar solvent,... Agent: Fasken Martineau Dumoulin LLP

20080008647 - Biodegradable polymer particles: Biodegradable polymer particles, as well as related compositions and methods, are disclosed.... Agent: Fish & Richardson PC

20080008648 - Treatment of cancer with a novel anti-il13 monoclonal antibody: The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies, The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.... Agent: Tanox, Inc.

20080008654 - Medical devices having a temporary radiopaque coating: The nanoparticles are formed of a metallic material and have surface modifications that impart water-dispersibility to the nanoparticles. The nanoparticles may be any of the various types of radiopaque water-dispersible metallic nanoparticles that are known in the art. The nanoparticles may be adapted to facilitate clearance through renal filtration or... Agent: Kenyon & Kenyon LLP

20080008665 - Flavors for oral compositions: The present invention relates to oral care compositions comprising stannous ions, a mint-type flavor oil, a protectant component that prevents generation of off odor and off taste in the composition, and orally acceptable carriers. The mint-type oils include peppermint, spearmint and corn mint. Suitable protectant components include copper salts and... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080008663 - Method of reducing inflammation: A method of reducing inflammation is provided. The method includes administering a chewing gum to an individual having an inflammatory condition such as heart disease. The chewing gum may further be administered to a subject lacking proper oral care.... Agent: Bell, Boyd & Lloyd LLP

20080008666 - Breath test for oral malodor: Measured of airway in samples a mammal, such as a human being, having oral malodor are analyzed for the presence of markers for the oral malodor. The mammal may subsequently be treated for this condition, and measured samples of airway breath again taken to determine the effectiveness of the treatment.... Agent: Day Pitney LLP

20080008667 - Flavor oils with reduced sulfur content and use in oral care compositions: The present invention relates to flavor oils including mint-, fruit- and spice-type flavors that are specially processed to substantially eliminate low-molecular weight sulfur compounds, in particular dimethyl sulfoxide (DMSO), which has been found to be the main precursor of malodorous species such as dimethyl sulfide and methyl mercaptan. These malodorous... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080008672 - Low temperature-stable creamy wash composition: Creamy wash composition containing (A) at least one N-long-chain-acyl acidic amino acid or a salt thereof, (B) at least one polyhydric alcohol, (C) at least one nonionic surfactant, (D) at least one salt of a divalent or higher cation and a monovalent or higher anion, and (E) water are stable... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080008676 - Deodorant composition comprising metallic deodorizing agent: A deodorant composition comprising (i) a metallic deodorizing agent selected from copper, zinc, silver, platinum, nickel, iron, cobalt, a copper compound, a zinc compound, a silver compound, a platinum compound, a nickel compound, an iron compound, a cobalt compound and a mixture thereof, (ii) an carboxylic group-containing gelling polymer; and... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080008678 - Aerosol paint composition with fungicide and sprayable aerosol composition: An aerosol paint composition includes an alkyd resin; one or more solvents; an organoclay; an anti-settling wax; a dispersing agent; one or more pigments; a drying agent; an anti-skinning agent; a fragrance; and a fungicide.... Agent: Greenblum & Bernstein, P.L.C

20080008679 - Osteoinduction-assisting composition: The present invention relates to a novel reactive medical substance having the bone restoration function, comprising a particular methacrylic acid ester, polymer and osteogenic factor. The reactive medical substance of the present invention has a mechanical strength which is increased by a reaction and is used in a living body... Agent: Stevens Davis Miller & Mosher, LLP

20080008687 - Transposon-based targeting system: The present invention relates to a targeting system comprising, preferably as distinct components, (a) a transposon which is devoid of a polynucleotide encoding a functional transposase comprising a polynucleotide of interest; and (b) a fusion protein comprising (ba) a transposase or a fragment or derivative thereof having transposase function; and... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080008649 - Gastrin releasing peptide compounds: Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. Novel methods... Agent: Kramer Levin Naftalis & Frankel LLP

20080008650 - Endometriosis cell targeting peptide and uses thereof: Provided herein are compositions and methods for selectively targeting an endometriosis cell.... Agent: Needle & Rosenberg, P.C.

20080008651 - Screening methods and transgenic animals for the treatment of beta-globin related disease and conditions: The orphan nuclear receptors TR2 and TR4 together constitute the DNA binding core of the 540 kDa DRED complex, a putative repressor of the human embryonic ε- and fetal γ-globin genes. Here the functional consequences of TR2 and TR4 germ line loss of function were examined, transgenic gain of function... Agent: Marshall, Gerstein & Borun LLP

20080008652 - Methods and compositions for mediation of immune responses and adjuvant activity: The present invention relates to methods and compositions for modulating immune responses and adjuvant activity. In particular, the present invention provides methods and compositions for screening for compounds that modulate cryopyrin signaling.... Agent: Casimir Jones, S.c.

20080008653 - Models for vaccine assessment: The present invention is directed to methods for constructing and using in vivo and in vitro models of aspects of human immunity and, in particular, construction of a human immune system model for the testing of, for example, vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. The present... Agent: Merchant & Gould PC

20080008658 - Contrast agent formulations for the visualization of the lymphatic system: The present invention relates to the field of diagnostic imaging and provides compositions of ultrasound contrast agents, particularly gas-filled microvesicles suspensions, in combination with vital dyes. The compositions of the invention are advantageously used in the visualization of the lymphatic system, particularly for the detection of the sentinel lymph node... Agent: Bracco Research Usa Inc.

20080008657 - Gas- filled microvesicles composition for contrast imaging: The present invention relates to a new composition comprising gas-filled microvesicles for contrast imaging which are particularly suitable for providing an effective echo response to at least two selected ultrasound waves having different frequencies. Said composition preferably comprises at least two different preparations of gas-filled microvesicles, which preferably have respective... Agent: Bracco Research Usa Inc.

20080008656 - Agent for enhancing contrast of image of fluorescent staining of lumen of digestive tract: It is intended to provide means for more clearly showing an image of fluorescent staining of a lumen of the digestive tract. The present invention provides an agent for enhancing a contrast of an image of fluorescent staining of a lumen of the digestive tract with an intravenously administered fluorescent... Agent: Greenblum & Bernstein, P.L.C

20080008655 - Tumor-targeted optical contrast agents: Cyanine dye bioconjugates useful for diagnostic imaging and therapy are disclosed. The conjugates include several cyanine dyes with a variety of bis- and tetrakis (carboxylic acid) homologs. The compounds may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of the compounds allows more... Agent: Wood, Herron & Evans, LLP

20080008659 - Oral dosage form comprising an antimisuse system: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form... Agent: Patton Boggs LLP

20080008662 - Aerosol drug inhibition of lung cancer: The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in... Agent: Fulbright & Jaworski, L.L.P.

20080008660 - Antimicrobially active compounds for treating bad breath: e

20080008661 - Methods and compositions for treating erectile dysfunction: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation... Agent: Bozicevic, Field & Francis LLP

20080008664 - Method of reducing infection: A method of reducing infection is provided. The method includes administering a chewing gum to a subject having an infection. The infection may include a nosocomial infection. The chewing gum may be administered to a subject lacking proper oral care.... Agent: Bell, Boyd & Lloyd LLP

20080008668 - Personal care compositions with glycerin and hydroxypropyl quaternary ammonium salts: A personal care composition is provided formulated with glycerin and a moisturization enhancing agent which is a salt of structure AB, wherein A is a cationic charged component, B is an anionic charged component, and A has at least one quaternized nitrogen atom and at least two hydroxyl groups and... Agent: Unilever Intellectual Property Group

20080008669 - Photostable sunscreen compositions comprising cinnamate ester uv-b filters and s-triazine compounds: Photostable sunscreen compositions containing at least one cinnamic acid ester UV-B filter and at least one particular s-triazine compound have improved effectiveness with respect to UV-B radiation.... Agent: Buchanan, Ingersoll & Rooney PC

20080008670 - Process for colouring dark skin: The present invention relates to a process for making up dark skin, comprising the application to the said skin of a composition comprising, in a physiologically acceptable medium, at least one direct colouring system in dissolved form, the said composition also having a viscosity of greater than 100 centipoises and... Agent: Oliff & Berridge, PLC

20080008671 - Assortment of antiperspirants having varying product performance characteristics: An array of antiperspirant products, comprising a first antiperspirant product that is marketed to male consumers and marketed as clinical strength or prescription strength; and a second antiperspirant product that is marketed to female consumers and marketed as clinical strength or prescription strength.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080008673 - Compositions comprising at least one c-glycoside derivative: The present disclosure relates to the combination of at least one C-glycoside derivative with at least one additional cosmetic or dermatological ingredient and/or active agent. Disclosed herein are cosmetic and/or dermatological compositions containing such a combination in a physiologically acceptable medium, or alternatively, a cosmetic or dermatological assembly comprising at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080008674 - Use of c-glycoside derivative for improving the skin's barrier function: The present invention relates to a cosmetic method for improving and/or reinforcing the skin's barrier function comprising at least a step of applying to the skin a composition comprising at least one C-glycoside derivative.... Agent: Oliff & Berridge, PLC

20080008675 - Odor eliminating items and methods of use for hunting: A regimen for hunting includes using a number of zeolite-containing personal items in connection with a hunter's apparel and body to reduce the hunter's scent for improved hunting. The personal items include mouthwash, deodorant/anti-perspirant, body and boot powder, bar and liquid soap for cleansing the body and hair, laundry detergent... Agent: Clark & Brody

20080008677 - Compositions comprising at least one organic polymer and a mixture of volatile and nonvolatile solvents: Compositions, for example cosmetic compositions, comprising at least one organic polymer, such as a crosslinked organosoluble polymer, and a mixture of at least two solvents, one of which is volatile and incompatible with the polymer, and the other of which is nonvolatile and compatible with the polymer. These compositions make... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080008680 - Antagonists of interleukin-15: Disclosed herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.... Agent: Fish & Richardson PC

20080008681 - Macrocyclic hepatitis c virus serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080008682 - Modulators of toll-like receptor 7: i

20080008684 - Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.... Agent: Howson And Howson

20080008683 - Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins: e

20080008686 - Tetracycline repressor regulated oncolytic viruses: The present invention is directed oncolytic Herpes simplex-l viruses whose replication is controlled using a tetracycline operator/repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors.... Agent: Law Office Of Michael A. Sanzo, LLC

20080008685 - Viral vectors: The present invention provides a plasmid encoding a replication-competent virus for use in therapy more particularly for use in the treatment of a cell proliferative disease, an immunological disease, a neuronal disorder, an acquired infection and inflammation as well as formulations comprising such plasmids together with a transfection agent.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080008690 - Aav virions with decreased immunoreactivity and uses therefor: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.... Agent: Robins & Pasternak

20080008689 - Method for transdifferentiation of non pancreatic stem cells to the pancreatic differentiation pathway: The subject invention comprises culture methods for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway. It also concerns the endocrine hormones that can be produced by such cultures, and the use of the transdifferentiated cells in the treatment of pancreatic diseases.... Agent: Swanson & Bratschun, L.L.C.

20080008691 - Modified growth hormone: The invention provides a nucleic acid molecule encoding a growth hormone (GH) which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides as well as a nucleic acid molecule encoding... Agent: Leydig, Voit & Mayer, Ltd.

20080008688 - System and method for genetically treating cardiac conduction disturbances: The present invention provides delivery systems for and methods of delivering conduction protein genetic material to cardiac cells in localized areas of the heart to improve the conductance therein. More specifically, there is provided a system and method for delivering connexin proteins or nucleic acid molecules encoding connexin proteins to... Agent: Medtronic, Inc.

20080008692 - Methods and compositions for altering cell function: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g.,... Agent: Medlen & Carroll, LLP

20080008693 - Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use: The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma... Agent: Townsend And Townsend And Crew, LLP

20080008694 - Methods to prevent and treat diseases: This invention discloses methods and compositions that can treat a variety of tissue injuries and infections. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20080008695 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof: The present invention is directed to phenylalanine ammonia-lyase (PAL) produced by prokaryotes, wherein such prokaryotic PAL wherein the PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention thus provides compositions of bacterial PAL and biologically active fragments, mutants, variants and... Agent: Biomarin Pharmaceutical Inc.

20080008696 - Markers for differential diagnosis and methods of use thereof: The present invention provides methods for the identification and use of diagnostic markers for differential diagnosis of diseases. In various aspects, the invention relates to methods and compositions able to determine the presence or absence of one, and preferably a plurality, of diseases that exhibit one or more similar or... Agent: Foley & Lardner LLP

20080008697 - Polynucleotides encoding novel pcsk9 variants: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the... Agent: Louis J. Wille Bristol-myers Squibb Company

20080008698 - Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions: A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment... Agent: Denis A. Polyn Bausch & Lomb Incorporated

20080008699 - Method for proteomic analysis utilizing immune recognition and cumulative subtraction: A method of identifying proteins in a proteome comprises the steps of: (a) immunizing a host organism with a sample containing an initial mixture of proteins from a tissue or fluid to be evaluated to elicit an antibody response to one or more proteins in the initial mixture; (b) isolating... Agent: Olson & Cepuritis, Ltd.

20080008700 - Multimeric fc receptor polypeptides: A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fcγ receptors (FcγR) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an FcγR type receptor and, particularly, FcγRIIa.... Agent: Sheridan Ross PC

20080008701 - C-met receptor regulation by angiotensin iv (at4) receptor ligands: The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis cancer metastasis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat... Agent: Seed Intellectual Property Law Group PLLC

20080008702 - Antibody immunization therapy for treatment of atherosclerosis: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method... Agent: Gauthier & Connors, LLP

20080008706 - B7s1: an immune modulator: The invention provides B7S1 nucleic acid, B7S1 polypeptides, and antibodies that bind B7S1 polypeptides. B7S1 sequences can be used, e.g., to screen for modulators of B7S1 activity. Modulators, e.g., antibodies or small molecules, can be used for the treatment of disease that involve an immune response.... Agent: Townsend And Townsend And Crew, LLP

20080008705 - Cancer prognostic diagnostic and treatment methods: The invention disclosed herein provides methods comprising detection of EphB2 polypeptide and/or polynucleotide in a biological sample from a subject, wherein the detection of EphB2 is predictive or indicative of cancer prognosis for the subject. The invention also provides methods for selecting cancer treatment, methods comprising detection of EphB2 polypeptide... Agent: Genentech, Inc.

20080008707 - Denatured collagen peptides and uses thereof: The invention provides peptide antagonists, such as synthetic collagen peptides. The invention provides antibody antagonists, or functional fragments thereof, that preferentially bind to denatured extracellular matrix components. It additionally provides methods for using the antagonists for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion,... Agent: Wilson Sonsini Goodrich & Rosati

20080008703 - Humanized antibody specific for tumor necrosis factor-alpha: Humanized antibodies specifically binding to hTNF-α are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the original mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a... Agent: Sughrue Mion, PLLC

20080008704 - Methods of treating colorectal cancer with anti-epidermal growth factor antibodies: A method for treating colorectal cancer is disclosed and consists of administering to a patient in need of such treatment a pharmaceutically effective dose of an agent capable of blocking the binding of EGF-receptor to its natural ligand(s) and/or inhibiting EGF-receptor-mediated signaling. Also disclosed is a method of increasing a... Agent: Kenyon & Kenyon LLP

20080008708 - Tyrosine kinase inhibitors: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts,... Agent: Merck And Co., Inc

20080008709 - Conjugation of biomolecules using diels-alder cycloaddition: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous... Agent: Klarquist Sparkman, LLP

20080008710 - Therapeutic agent and diagnostic agent for cholangiocarcinoma: Disclosed is a cholangiocarcinoma cell growth inhibitor comprising an anti-glypican-3 antibody as an active ingredient. Preferably, the anti-glypican-3 antibody has a cytotoxic activity such as an antibody-dependent cytotoxic (ADCC) activity and a complement-dependent cytotoxic (CDC) activity. Also disclosed is a diagnostic agent for diagnosis of cholangiocarcinoma comprising an anti-glypican-3 antibody.... Agent: Fish & Richardson PC

20080008711 - Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancers: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20080008712 - Novel phosphorylated sequences of the phosphatase cdc25b, antibodies for said sequences and use thereof: i

20080008713 - Single domain antibodies against tnfr1 and methods of use therefor: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080008714 - Tweak receptor agonists as anti-angiogenic agents: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.... Agent: Fish & Richardson PC

20080008715 - Ulbp antibodies: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the... Agent: Immunex Corporation Law Department

20080008716 - Combined pharmaceutical composition comprising an anti-4-1bb monoclonal antibody and chemotherapeutic anti-cancer agent for preventing and treating cancer disease: A combined composition comprising an anti-4-1BB monoclonal antibody and chemotherapeutic anti-cancer agent for preventing and treating cancer disease. Provides a pharmaceutical composition comprising the combined mixture of anti-4-1BB antibody and chemotherapeutic anti-cancer agent enhancing the specific immune response to cancer and killing cancer cell for treating or preventing cancer disease... Agent: Kirk Hahn

20080008717 - Polynucleotide fragments of an infectious human endogenous retrovirus: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences,... Agent: Fulbright & Jaworski L.L.P.

20080008718 - Ornithobacterium rhinotracheale subunit vaccines: The present invention relates to nucleic acids encoding Ornithobacterium rhinotracheale proteins, to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acids, to Ornithobacterium rhinotracheale proteins, to antibodies against such proteins, to such proteins for use in vaccines, to the use of such proteins in... Agent: Intervet Inc. Patent Department

20080008719 - Methods and compositions for the treatment of prostate cancer: The present application relates to methods and compositions for the treatment of cancer. In specific embodiments, the application relates to the use of antibodies capable of modulating CDCP1 as therapeutic agents for the treatment of cancer and as diagnostic agents for the detection of and/or prognosis of cancer.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080008720 - Substituted tricyclic heterocycles and their uses: Disclosed are substituted tricyclic heterocycle compounds of the formulas (I), (II) and (III) shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080008721 - Preventive and therapeutic use of polypeptides from african swine virus as vaccines: The present invention relates to the use of selected polypeptides from African Swine virus for the prevention and therapy of African Swine infections as well as other infections, including immune deficiencies in mammals and humans.... Agent: Ali Kamarei, Esq.

20080008722 - Fusion protein of porcine reproductive and respiratory syndrome virus as prrs vaccine: The present invention provides a PRRSV subunit vaccine comprising a fusion protein having neutralization titers evoked, PE-PQGAB-K3, which comprises a chimeric polypeptide containing N-terminal portions of PRRSV ORF5 and ORF6 structure proteins; a portion of Pseudomonas exotoxin A binding and translocation domain; and a carboxyl terminal domain containing KDEL-KDEL-KDEL(K3) sequence.... Agent: Bacon & Thomas, PLLC

20080008723 - Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates: A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed... Agent: Borden Ladner Gervais LLP Anne Kinsman

20080008724 - Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails: A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves by immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap)... Agent: Howson And Howson

20080008725 - Influenza recombinant subunit vaccine: The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in... Agent: George E. Darby

20080008726 - Vaccine composition against rhodococcus equi: The invention concerns a method for preparing a soluble antigenic extract from Rhodococcus equi, comprising a step of solubilizing membranes of said bacteria by contacting said bacteria with an extraction solution containing a nonionic detergent of sorbitan polyethylene fatty acid ester type. The invention also concerns a soluble antigenic extract... Agent: Foley And Lardner LLP Suite 500

20080008729 - Flavor oils with reduced sulfur content and use in oral care compositions: The present invention relates to flavor oils including mint-, fruit- and spice-type flavors that are specially processed to substantially eliminate low-molecular weight sulfur compounds, in particular dimethyl sulfoxide (DMSO), which has been found to be the main precursor of malodorous species such as dimethyl sulfide and methyl mercaptan. These malodorous... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080008727 - Compositions comprising adapalene dissolved with cyclodextrins: Cosmetic/pharmaceutical compositions comprising adapalene dissolved in an aqueous medium with cyclodextrin and/or derivatives thereof, notably as inclusion complexes therewith, are useful as cosmetics and for the therapeutic treatment, e.g., of acne.... Agent: Buchanan, Ingersoll & Rooney PC

20080008730 - Cosmetic compositions and methods for reducing the appearance of pores: A cosmetic composition and method for reducing the appearance of pores. The composition is based on a silicone elastomer or a water soluble or dispersible polymer and light scattering particles, and having a specified unique rheological profile. The inventive compositions and methods deliver an improvement in appearance of pores of... Agent: Unilever Intellectual Property Group

20080008728 - Dehydrated dentifrice and toothbrush: A toothbrush has one or two part-spherical pockets formed in the brush surface. Balls or pellets of matching shape of dehydrated toothpaste are placed in the depressions, the brush is wetted and the pellets turn to a gel, ready for brushing. The pellets may be of various colors and flavors... Agent: David A. Greenlee

20080008731 - Pet collar with replaceable insecticide element: A semi-flexible insecticide strip is removably attached to the belt of a pelt collar to regenerate a pest-killing medicament and increase its efficacy. The strip is secured to the belt surface that faces the animal skin or fur by attachment loops or edged retainers that are generally perpendicular to the... Agent: Ernest D. Buff Ernest D. Buff And Associates, LLC.

20080008732 - Chalkbrood determent: The invention provides a means of deterring chalkbrood which is safer to honeybees and effective for a prolonged period. A chalkbrood determent comprising a carrier having a mixture of an isothiocyanate ester and an organic acid triglyceride and/or a rosin compound fixed to a carrier material with an embedding material... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080008733 - Controlled release compositions for interferon based on pegt/pbt block copolymers: The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of... Agent: Banner & Witcoff, Ltd.

20080008735 - Process for manufacturing a stationary state of crystalline polymer of a biodegradable polymer matrix carrying an active substance and a polymer matrix produced thereby: A method for manufacturing a stationary state of polymer crystallinity of an active substance charged polylactide matrix for a stent, comprising the steps of: preparing the active substance charged polylactide matrix containing (a) a polylactide in amorphous or semicrystalline modification or with amorphous domains, and (b) at least one active... Agent: Powell Goldstein LLP

20080008736 - Random copolymers of methacrylates and acrylates: A random copolymer including units derived from at least two groups of monomers (a) an alkyl acrylate or methacrylate, (b) an alkoxyalkyl acrylate or methacrylate, and (c) a hydrophilic acrylate or methacrylate and coatings formed thereof are provided.... Agent: Squire, Sanders & Dempsey LLP

20080008734 - Reduction of skin irritation caused by biomedical electrodes: A method and/or composition for monitoring electrical signals from a patient through a biomedical electrode or delivering an effective amount of electrical stimulation to said patient without causing erythema which comprises providing an antioxidant to the skin of said patient via solution, lotion, or gel prior to adhering said biomedical... Agent: Walter A. Hackler, Ph.d. Patent Law Office

20080008737 - Bone delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080008738 - Flexible bioresorbable hemostatic packing and stent: The invention provides a flexible bioresorbable foam having hemostatic properties. The foam is formed from a carboxymethylcellulose suspension.... Agent: Dicke, Billig & Czaja, PLLC Attn: Md Matters

20080008739 - Phase-separated block copolymer coatings for implantable medical devices: Medical devices and coatings for medical devices are disclosed, including methods for forming the devices and coatings. The devices and coatings comprise a phase-separated block copolymer matrix and one or more active agents. The phase-separated block copolymer matrix can be used to modulate the release-rate of one or more active... Agent: Squire, Sanders & Dempsey LLP

20080008740 - Pharmaceutical composition for rectal, or vaginal application, method of manufacturing and use as medicament thereof: A each independently is an —NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1... Agent: Notaro And Michalos

20080008741 - Methods of treating irritable bowel syndrome: The present invention provides methods of treating irritable bowel syndrome (IBS) in an individual suffering from IBS. The methods generally involve administering to the individual an effective amount of a therapeutic nucleic acid. The invention further provides kits and compositions for practicing the subject methods.... Agent: Bozicevic, Field & Francis LLP

20080008742 - Chewy products and methods for making the same: Methods for producing chewable emulsion compositions and compositions produced from such methods are disclosed. The emulsion base may be prepared by contacting an aqueous phase and a nonaqueous phase in the presence of an emulsifier. The aqueous phase is prepared under conditions that permit no substantial moisture loss and reduced... Agent: Buchanan, Ingersoll & Rooney PC

20080008743 - Orally dissolving formulations of memantine: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to... Agent: Forest Laboratories, Inc. Att: Michael Ciraolo

20080008744 - Novel tissue support: The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to... Agent: Covidien

20080008745 - Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles: The present invention provides methods for transdermal delivery of a therapeutically effective amount of Naltrexone Hydrochloride, Naltrexol Hydrochloride, and/or Naltrexone Diol Ester using microneedles. The invention also provides methods for treatment of narcotic dependence, alcohol abuse, and/or alcoholism. Preferably, the Naltrexone Hydrochloride, Naltrexol Hydrochloride, and/or Naltrexone Diol Ester is administered... Agent: Buchanan, Ingersoll & Rooney PC

20080008746 - Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate: The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive,... Agent: Foley And Lardner LLP Suite 500

20080008747 - Transdermal patch: A transdermal patch for administrating an agonist to a patient, where the transdermal patch includes an occlusive wall defining a reservoir with an open bottom end and an opposing top end, a matrix permeable to perspiration from the patient occupying the reservoir, wherein the matrix includes a first region having... Agent: Kenneth Watov, Esq. Watov & Kipnes, P.C.

20080008748 - Method for treating pain using a substituted 2-aminotetralin compound: A method for treating pain, particularly non-inflammatory musculoskeletal pain such as fibromyalgia, myofascial pain or back pain, in a subject comprises administering to the subject a substituted 2-aminotetralin compound as defined herein, illustratively rotigotine.... Agent: Harness, Dickey, & Pierce, P.l.c

20080008749 - Ceramide composition and method of use: A method for treating and preventing diseases associated with neutrophil infiltration, particularly ocular diseases, is provided, which method comprises administering to a subject in need thereof an effective amount of ceramide or a derivative thereof. Also provided is a composition for treating diseases associated with neutrophil infiltration, the composition comprising... Agent: Heidi A. Boehlefeld, Esq. Renner, Otto, Boisselle & Sklar, LLP

20080008750 - Band-seals for hard capsules: The present invention has as its object to provide a band-seal to manufacture a leak-tight, stable hard capsule preparation not being susceptible to deformation after having filled pharmaceuticals, foods, healthy foods, etc. in a hard capsule comprising a polyvinyl alcohol copolymer or pullulan as a base, and in more particular,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080008752 - Pharmaceutical compositions of memantine: The invention is directed to easily dissolved, stable dose proportional pharmaceutical compositions, comprising granulated memantine and methods of preparing the same. In particular, the invention is directed to granulated memantine pharmaceutical compositions in the form of film coated tablets.... Agent: Kenyon & Kenyon LLP

20080008751 - Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof: The present invention provides stable pharmaceutical compositions comprising a combination of active pharmaceutical ingredients. The pharmaceutical composition of the present invention comprises a moisture sensitive drug, in particular an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril, as an active ingredient, a second pharmaceutically active ingredient such as for example... Agent: Kenyon & Kenyon LLP

20080008753 - Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic... Agent: O'melveny & Myers LLP

20080008754 - Pharmaceutical compositions comprising (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol: Novel pharmaceutical compositions, particularly sustained release pharmaceutical compositions, of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or pharmaceutically acceptable salts or solvates thereof are disclosed.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080008755 - Pharmaceutical formulation of cholanic acid-chitosan complex incorporated with hydrophobic anticancer drugs and preparation method thereof: Disclosed are a pharmaceutical formulation characterized in that hydrophobic anticancer drugs are incorporated into a cholanic acid-chitosan complex and a preparation method thereof, and more particularly, the cholanic acid-chitosan complex composing of hydrophobic cholanic acid and hydrophilic chitosan forms self-aggregates in an aquatic environment. The pharmaceutical formulation characterized in that... Agent: Lucas & Mercanti, LLP

20080008756 - Homogenous solid matrix containing vegetable protein: The present invention relates to a homogeneous solid matrix composition containing vegetable proteins, lecithin and at least one ingestible bioactive compound which is at least partially insoluble in an aqueous medium.... Agent: Townsend And Townsend And Crew, LLP

20080008757 - Metal oxide dispersions: A dispersion contains particles of metal oxide dispersed in a siloxane fluid and a dispersing agent which is a polysiloxane wherein (i) the polysiloxane contains in the range from 0.1 to 3 carboxyl groups, and (ii) the ratio of non-carboxyl group containing monomer units to carboxyl group containing monomer units... Agent: Jones Day

20080008758 - Granulate-matrix: Composition comprising a granulate selected from the group consisting of autogenous bone material, bone/bone like material from natural sources, synthetic materials and mixtures thereof and a matrix obtainable by a self selective reaction of at least two precursors A and B in the presence of water. A kit for preparing... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20080008759 - Method of improving wound healing: The present invention relates to method of wound healing. More particularly, the present invention is directed to of treating wounds using ionomer resins. The invention involves treating the injured tissue with biocompatible crosslinked resins that optionally contain leachable healing and anti-biotic agents.... Agent: Crowell & Moring LLP Intellectual Property Group

20080008763 - Composition and methods for the enterosorption and management of toxins: A composition and method for use as a preventive therapy to mitigate the effects of environmental toxins, and particularly aflatoxins in a subject. The subject may be at risk for hepatocellular carcinoma and aflatoxicosis. The composition comprising: an effective amount of an isolated low sodium, calcium aluminosilicate clay in a... Agent: Jackson Walker LLP

20080008760 - Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry: The present invention relates to functionalized carbon nanotubes, a process for preparing the same and their use, in particular in medicinal chemistry and more particularly in immunology.... Agent: Young & Thompson

20080008761 - Pharmaceutical formulation administrable orally in terms of a taste, consistency and a dosing: A method for preparing a pharmaceutical formulation which is orally administrable in terms of a taste, consistency and a dosing, including the steps of (a) grinding a solid pharmaceutical formulation containing one or several active substances and excipients in such a way that a powder is obtained, and (b) mixing... Agent: Dennison, Schultz & Macdonald

20080008762 - Steroid formulation and methods of treatment using same: The invention provides steroid-containing pharmaceutical compositions which are free of classical preservatives and preferably comprise a steroid that is sparingly soluble or substantially insoluble in water, particulate steroid having an average particle size of from about 2.2 to about 10 microns. The pharmaceutical compositions can be used to treat medical... Agent: Edwards Angell Palmer & Dodge LLP (client Reference No. 47992)

20080008764 - Carbon-substituted diketopiperazine delivery systems: Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and administering these compositions are also provided.... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20080008765 - Taste-masking pharmaceutical compositions: The present invention relates to a pharmaceutical composition for oral administration suitable for the preparation of a ready-to-use suspension comprising coated particles comprising an active substance having an unpleasant and/or bitter taste, such as clarithromycin, and a suspension base comprising an osmotically active substance capable of providing a high osmolality... Agent: Novartis Corporate Intellectual Property

20080008766 - Methods of repairing bone: This invention relates to an improved method of preparing an implantable gel or paste for placement between injured bones or placement in bony voids to induce regeneration, and the compositions produced thereby. Specifically, mineral, ceramic, or processed bone particles are coated with a high molecular weight polymer capable of forming... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080008767 - Methods and compositions for controlling parasitic infections of animals: A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca.... Agent: King & Schickli, PLLC

20080008768 - Compositions and methods for inhibiting sonic hedgehog activity: The present invention relates to the use of sonic hedgehog antagonists in the prevention and treatment of cancer and other hyperproliferative diseases or disorders. Methods for identifying such antagonists are also provided.... Agent: Licata & Tyrrell P.C.

20080008769 - Treatment of urinary tract infections: The invention provides a method for treating urinary tract infections in a patient by providing a mouth rinsing composition which releases free molecular iodine into the mucous membranes which enters into the urinary tract.... Agent: John Lezdey & Associates

20080008770 - Composition for weight reduction comprising capsaicin, green tea extract, l-tyrosine and caffeine: A composition for reducing the weight of a human. The composition is provided in the form of a capsule comprising an effective amount of capsaicin and/or analogs thereof, L-tyrosine, supplemental caffeine and/or and analogs thereof, green tea extract containing catechin and caffeine, and embodiments which include calcium. The invention is... Agent: Gordon & Rees LLP

20080008771 - Nitric oxide dioxygenase inhibitors: A method and composition to inhibit the enzyme nitric oxide dioxygenase (NOD) and therefore accumulate nitric oxide (NO) in cells or tissues. By preventing NO removal, the inhibitors may effect cellular signaling, modulate vasotension, enhance O2 delivery to tissues, and provide antibiotic and/or antineoplastic effects. Inhibitors include compounds that bind... Agent: Wood, Herron & Evans, LLP

20080008772 - Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction: The present invention relates to compositions that comprise immediate release and extended release guaifenesin, and extended release hydrocodone bitartrate. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Attn: Ellen Klann

20080008773 - Food beverage or feed for the promotion of osteogenesis comprising umbelliferae, liliaceae or compositae plant species: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring promotion of osteogenesis or enhancement of bone morphogenetic protein production, an agent for promotion of osteogenesis or an agent for enhancement of bone morphogenetic protein production, and a food, beverage or feed for promotion of... Agent: Birch Stewart Kolasch & Birch

20080008774 - Use of plants, plant extracts and nature-identical components from plants to affect the rumen fermentation and to improve the energy and protein retention of ruminants: Use of an plant materials, plant extracts or nature-identical components selected from Lonicera japonica, Gentiana asclepidea, Gentiana lutea, Eugenia caryophyllata, Bellis perennis, Olea europaea, Symphytum officinale, Carduus pycnocephalus, Paeoniae alba radix, Populus tremula, Prunus avium, Salix caprea, Rheum nobile, Helianthemum canum, Arctostaphylos uva-ursi, Peltiphyllum peltatum, Epilobium montanum, Knautia arvensis, Latuca... Agent: Nixon & Vanderhye, PC

20080008775 - Method for treating diabetic vascular complications: The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20080008776 - Natural extract containing xanthohumol, and method for the production thereof products produced therefrom: The invention relates to a method for producing an extract containing xanthohumol (XN), which is obtained from toasted cereal products, cereal malt, coffee or cocoa. The XN-content in said extract is in the region of 10 mg/kg-2 g/kg xanthohumol. The use of XN-toasted extracts enables the XN-content of foodstuffs and... Agent: Hoxie & Associates LLC

20080008777 - Methods of treating a bunion: A method is for treating a bunion in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a liquid solution that includes a botulinum toxin to a location of the bunion of the patient. The administration of the botulinum toxin reduces at... Agent: Knobbe Martens Olson & Bear LLP